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Preface  
Febrile neutropenia in cancer patients can be fatal. Can we predict which patients are at 
high risk of febrile neutropenia and target prophylactic measures to those patients? To 
answer this question, it is essential to know the incidence of neutropenia in cancer patients, 
to identify risk factors of febrile neutropenia and effective prophylactic measures. The aim 
of this work was to describe the epidemiology of neutropenia and febrile neutropenia 
including risk factors, to develop and externally validate a risk prediction model for febrile 
neutropenia, and to summarise the efficacy of prophylactic measures for neutropenia. This 
work is based on four published studies and the thesis is structured as follows.   
First, a general and more specific introduction to the research addressed in this work is 
provided. The general introduction deals with a short description of epidemiology and its 
basic principles and terminology including epidemiologic study designs (1.1). This is 
complemented by a more specific introduction that provides an overview of cancer and 
neutropenia including a short summary for breast cancer, chronic lymphocytic leukaemia 
(CLL) and neutropenia (1.2). A brief section following the introduction describes the overall 
objectives of the thesis (2).  
In the methods’ section, the Poisson regression used to identify trends in incidence is 
explained (3.2.2). Other regression analyses include logistic regression (3.2.1) to 
determine risk factors and to develop a risk prediction model and Cox proportional hazard 
regression (3.2.3) to analyse survival data. The approach for a systematic review is briefly 
described (3.3).  
In a separate results’ section (4), the methodological details and results of the four peer-
reviewed publications this work is based on are reproduced. Finally, the findings of the 
studies are discussed in a broader context and potential future directions are presented 
(5), and conclusions are drawn (6). A comprehensive reference list is provided (7). 
Supplementary material is available in the Appendix (8).   
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Summary 
Epidemiology studies the causes and distribution of population health and disease 
conditions in defined populations. It identifies risk factors for disease which may help to 
prevent disease and promote health.  
Each year, the American Cancer Society describes the epidemiology of cancer in the USA. 
Breast cancer and CLL are the most common cancers in women and adults, respectively. 
European data for CLL are limited. For both cancers, chemotherapy is an important 
treatment option. But side effects such as neutropenia and infections remain the principal 
dose-limiting toxicities, which may affect the effectiveness of cancer chemotherapy. 
Several studies evaluated risk factors for chemotherapy-induced neutropenia (CIN; 
absolute neutrophil count [ANC] <1.5x109/L) and febrile neutropenia (FN; ANC <0.5x109/L 
and oral temperature ≥38° for more than 1 hour): e.g. older age, recent infection, prior 
chemotherapy, and planned relative dose intensity greater than 85% of standard 
chemotherapy dosing. The prophylactic use of granulocyte colony-stimulating factors (G-
CSFs) has been shown to be protective.  
Based on the above mentioned risk factors, a number of risk prediction models have been 
developed over the years. Very often, the risk prediction models considered patient-
related, tumour-related, treatment-related, or genetic factors. The majority of these models 
are not validated using an independent dataset. Systematic reviews of G-CSFs to prevent 
neutropenia are available, but do not include new long-acting G-CSFs or observational 
study designs. 
To address the epidemiology of CLL, the incidence and risk factors of CIN and FN, and to 
develop and externally validate a risk prediction model for the occurrence of FN including 
a broad range of risk factors, three quantitative studies were conducted and published. The 
fourth published study summarised the efficacy, effectiveness and safety of G-CSFs for 
the prevention of CIN and FN. 
For the first study, the author conducted a cohort analysis of the UK Clinical Practice 
Research Datalink (CPRD) to identify the epidemiology of CLL, the incidence of 
neutropenia, and changes in medical resource utilisation of CLL patients. Due to limited 
data regarding the incidence of neutropenia, the study focused on the epidemiology of CLL 
and medical resource utilisation of CLL patients. The incidence of CLL was 6.2 per 100’000 
person-years and remained stable between 2006 and 2011. Medical resource utilisation in 
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CLL patients increased over the time period from 2000 to 2012. Primary care data from the 
UK CPRD seemed to be valid to determine the incidence of CLL. These data may not 
reflect the total of medical resource use in CLL patients as chemotherapy and treatment of 
related complications such as infections and neutropenia are mainly performed in 
secondary or tertiary care. 
The second study addressed the identification of risk factors and the development of a risk 
prediction model for FN in a hospital-based breast cancer cohort. Risk factors for FN were 
lower platelet count and haemoglobin, higher alanine aminotransferase (ALT), and specific 
allele variants of two single nucleotide polymorphisms (SNPs) in a gene involved in 
multidrug resistance. Genetic testing beforehand might be helpful to identify patients at a 
very high risk of FN. Predictive performance of the model was improved by adding genetic 
information but overall remained limited.  
The third study used an available risk prediction model for FN in Non-Hodgkin lymphoma 
(NHL) patients and applied its prediction rules to an independent dataset of NHL patients. 
Age, weight, baseline white blood cell count, and planned chemotherapy dose were 
confirmed to predict the risk of FN. However, there was a decrease of the predictive 
performance in the independent validation dataset. This limits its use in clinical practice. 
But if successful risk prediction models are developed and externally validated, these may 
help to optimally target prophylaxis with G-CSFs to those patients at high risk of FN. 
Finally, a systematic literature review was conducted to identify studies evaluating the 
efficacy, effectiveness and safety of G-CSFs in the prevention of CIN and FN. Most studies 
showed better efficacy and effectiveness for the long-acting pegfilgrastim than daily 
filgrastim. Efficacy and safety profiles of new long-acting G-CSFs such as lipegfilgrastim 
and balugrastim were comparable to pegfilgrastim. In times of increasing health care costs 
and scarce resources, the cost-efficient use of supportive measures is necessary. 
The studies this work is based on showed that the availability of and access to appropriate 
data sources are necessary to develop and systematically validate risk prediction models. 
The findings contribute to the development of an evidence-based, efficient and cost-
efficient approach to prevent neutropenia in cancer patients. 
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1 Introduction 
1.1 Epidemiology 
The word epidemiology originates from the Greek words “epi”, meaning among or on; 
“demos”, meaning population; and “logos” meaning study or discourse [1]. It is defined as 
the study of the distribution and determinants or risk factors of disease in a defined human 
population [2]. Epidemiology is the basic science of public health and may help to prevent 
disease and promote health of the population.  
Epidemiological studies were already conducted before the 19th century. Principles that 
still apply to good epidemiologic work have been manifested by the world’s first 
epidemiologist John Graunt (1620-1674) [3]. His first and only published work included 
several methodological aspects of epidemiology [4]. A prominent example of another 
epidemiological study is John Snow’s (1813-1858) study during cholera epidemics in 
London [2]. The physician demonstrated that only those who drank infected water from a 
specific water pump contracted the disease. Without knowing the disease-causing 
pathogen, he demonstrated the mode of transmission of cholera.  
In high-income countries, most infectious diseases were controllable after the introduction 
of hygiene measures, vaccinations and antibiotics, whereas non-communicable diseases 
such as cardiovascular disease and cancer became a major health burden [2]. To gain 
knowledge in non-infectious diseases, the USA initiated many population-based studies 
such as The Framingham Heart Study [5], the water fluoridation study [6] or the Smoking 
and Health study [7], where basic epidemiological principles were applied. A very famous 
and classic epidemiological study was published in 1950 by Sir Richard Doll and Sir Austin 
Bradford Hill [8]. They conducted a case-control study (see section 1.1.2.1 for a definition) 
that demonstrated a link between tobacco smoking and lung cancer. 
Important basic concepts of epidemiology were defined later. A pioneering work was 
published by Sir Austin Bradford Hill in 1965 defining criteria to separate causal from non-
causal explanations [9]. His published criteria were an expansion of the former US Surgeon 
General’s report criteria [7] and are described in the next section. Other statisticians that 
contributed significantly to the development of modern epidemiology were Jerome 
Cornfield, Nathan Mantel, Norman Breslow and Ross L. Prentice [10]. Many of their 
epidemiological concepts are still popular. 
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1.1.1 Basic concepts and terminology 
Three types of epidemiology can be distinguished; descriptive, analytical and interventional 
epidemiology [11]. Descriptive epidemiology aims to identify and classify disease entities 
and to describe the natural history of disease including transmission, distribution, and 
evolution of the disease. Usually, descriptive epidemiology does not generate hypotheses. 
In analytical epidemiology, a case group and a control group need to be defined to identify 
determinants and potential causes of the disease, to define risk factors, and to measure 
the level of risk. Interventional epidemiology defines health problems, and designs and 
measures the impact of solutions.  
The concept of analytical epidemiology is to describe an association between an exposure 
(e.g. smoking) and an outcome (e.g. lung cancer) or to describe causality [11]. Hill’s criteria 
for assessing causality are: the strength of association, i.e. how much higher is the risk of 
an outcome in the exposed compared to the unexposed group; consistency which means 
others have observed the same association; specificity in the sense of the association or 
the magnitude of the association; temporality meaning that the exposure precedes the 
outcome; a biological gradient, i.e. dose-response relationship; plausibility in terms of 
biologically plausible; coherence meaning that it does not interfere with the natural or 
biologic history of the disease; an experiment meaning that the avoidance of an exposure 
leads to less outcomes; and analogy with other exposure-outcome relationships [9]. 
Nowadays, in the context of multifactorial disease and research questions, the assessment 
of causality is more complex. Hill’s criteria may no longer be appropriate for assessing 
causality [4,12]. 
However, today’s definition of causality contains Hill’s concept of temporality. Causality is 
defined as the relationship between an event and a second event whereby the second 
event is a consequence of the first, i.e. the exposure must precede the outcome [13,14]. If 
there is an interest in the effect of a particular exposure, the effect is measured in an 
exposed population and the difference to the effect which would have been observed in 
the same, but non-exposed population is the effect due to the exposure we are interested 
in (counterfactual model) [15]. Confounding and bias (discussed in section 1.1.3), but also 
chance and reverse causality can provide alternative explanations for the observed 
differences in effect between the exposed and non-exposed groups.  
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1.1.2 Types of epidemiologic studies 
Based on the three types of epidemiology, descriptive, analytical and interventional 
epidemiology, six different types of studies can be distinguished (Figure 1.1-1) [11]. 
Figure 1.1-1: Most common types of epidemiological studies 
  
 
 
1.1.2.1 Cohort and case-control studies 
Conducting a cohort study, we consider one exposure (risk or protective factor) and 
observe if one or more outcomes of interest (e.g. disease or not) occur in the exposed (with 
risk factor) or non-exposed (without risk factor) groups which are followed over time [16]. 
The non-exposed group should be as similar as possible to the exposed group, except for 
the exposure of interest.  
In case-control studies, the outcome is given (e.g. cases are defined as having the disease 
and controls are defined as being disease-free) [17]. The frequency of one or more 
exposures in subjects with or without the outcome is assessed. Selection of the appropriate 
control group is crucial. In nested case-control studies, cases are identified during the 
cohort study.  
Cohort studies can be prospective, meaning that the population is observed forward in time 
and cases have not yet occurred, or retrospective, meaning that cases have already 
occurred and the study looks back in time as in case-control studies [18,19]. Retrospective 
studies are faster and cheaper than prospective studies, but the availability of exposure 
data can be problematic. Despite the additional effort compared to retrospective studies, 
Types of 
study design
Observational
Descriptive Ecological study
Analytical
Longitudinal 
study
Cohort study
- exposure -> 
outcomes
Case-control 
study
- outcome-> 
exposures
Cross-sectional 
study
-exposure and 
outcome 
simultaneouslyExperimental
Randomised 
controlled trial 
(RCT)
Time 
Prospective Retrospective 
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prospective studies are more frequent. The quality of data and the complete measurement 
of exposure can be ensured in prospective studies.  
1.1.2.2 Other study designs 
Randomised controlled trials (RCTs) are studies in which the efficacy of a health 
intervention is assessed in an experiment-like design [20]. Subjects are randomly allocated 
to an intervention. Random allocation ensures that other exposures or potential causal 
factors of the outcome are equally distributed between the intervention and the control 
group. It avoids confounding and minimises bias. Therefore, RCTs are the reference 
standard to show causation in medical research. However, RCTs may not be feasible for 
every research question due to ethical issues [21].  
Cross-sectional and longitudinal studies belong to the analytical epidemiological studies 
and are observational. In cross-sectional studies, a sample of the population at risk is 
observed at one point of time [22]. An example could be a survey that asks 1,000 people 
if they received a diagnosis of cancer or not to determine the prevalence rate of cancer in 
this population. In longitudinal studies, a group of people is prospectively followed over 
time [23]. Longitudinal studies allow calculating incidence rates, because new disease 
occurrences are registered. 
More recent types of epidemiological studies include the case-crossover [24] and the case-
time-control design [25,26]. In case-crossover studies, the case is used as its own control. 
This renders the case and control more similar. In case-time-control studies, the history of 
exposure of a conventional control group is used to adjust for the systematic error from 
temporal changes. These two study designs are often used in pharmacoepidemiological 
research [27,28].  
1.1.3 Validity in epidemiological studies 
Measurement errors define how well a study is capable of measuring what it intended to 
measure. A study is considered valid if it measured the truth or real situation in the 
population, no systematic errors are present and random errors are small [29].  
Random error can occur because in each study only a subsample of the entire population 
is included potentially leading to sampling error. Variation at random in individuals included 
in the study may also lead to random error. Random errors are less problematic for the 
validity of the study results than systematic errors.  
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Systematic error occurs if there is a systematic difference between what the study is 
estimating and what the study intended to estimate. It is more difficult to detect and to deal 
with systematic errors than random errors. There are two types of systematic errors, bias 
[30] and confounding [31].  
Bias occurs if differences in the intervention and control group are introduced by uneven 
decisions or assessments made among the groups [32,33]. Examples of biases are 
detection bias (e.g. women see the physician more often than men), selection bias (e.g. 
patients with poor prognosis are selected as controls), attrition bias (e.g. patients among 
case group follow study protocol more closely than patients among control group), 
reporting bias (e.g. only selective outcomes are reported), loss to follow-up (e.g. study 
participants do not show up because they have moved) and measurement bias (e.g. 
physical assessment is more thoroughly performed in cases than controls) [30, 32, 33].  
Confounding arises if other risk factors and potential causal factors of the outcome are not 
balanced between the case and control group [31]. A confounder is a factor that is 
associated with the exposure and with the outcome as presented in the directed acyclic 
graph (Figure 1.1-2) [34].  
Figure 1.1-2: Directed acyclic graph (DAG) 
 
 
In a study assessing the relationship between an exposure and an outcome, an instrumental variable is applied to remove 
confounding [35]. An instrumental variable is strongly associated with the exposure, but unrelated to confounders. 
Therefore, instrumental variables have only an effect on the outcome through their relationship with the exposure. 
 
Measured confounders 
Exposure Outcome Instrumental variable 
Unmeasured confounding 
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Confounding by indication refers to the fact that the clinical condition that determines the 
exposure is linked to the outcome, e.g. patients with more severe disease are more likely 
to receive the intervention and they have a higher risk of adverse outcome [36,37].  
Interaction or effect modification describes how a relationship between an exposure and 
an outcome is changed by adding an effect modifier [36]. The effect modifier must be a 
risk factor for the outcome. For example, age or gender are effect modifiers for many 
conditions. 
1.1.4 Basic epidemiological measures 
The basis for epidemiological measures is the contingency table or also called 2x2 table 
[38] presented in Figure 1.1-3. This table can be extended if more categories are available. 
Figure 1.1-3: Contingency table or 2x2 table 
Outcome 
Exposure*    
Cases Controls  
Exposed a (TP) b (FP) a+b 
Non-exposed c (FN) d (TN) c+d 
 a+c b+d N=a+b+c+d 
FN, false negative; FP, false positive; TN, true negative; TP, true positive 
* or test result that can be positive or negative; or classification of the model that can be positive or negative 
Prevalence proportions [39] are a measure of the outcome status and are defined as the 
proportion of subjects having the outcome in a given population at a single point in time 
((a+c)/N).  
Incidence proportions measure disease onset [39]. They can be calculated for the entire 
population ((a+c)/(a+b+c+d)) or separately for the exposed and the non-exposed groups 
by dividing the number of cases during a time period in the exposed and non-exposed 
group by the total number of exposed (a/(a+b)) or non-exposed subjects (c/(c+d)) during 
that time period in the study population, respectively. Relative risks (RRs) are derived by 
dividing the incidence proportions in exposed subjects by the incidence proportions in non-
exposed subjects ((a/(a+b))/(c/(c+d))). Incidence rates (IRs) are calculated by dividing the 
number of cases by the total time contributed by the subjects followed. IRs can be 
calculated for the exposed and the non-exposed group and incidence rate ratios (IRRs) 
can be derived. 
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Because in case-control studies the number of cases and controls is arbitrary, no incidence 
proportions can be calculated. Instead, odds ratios (ORs) are calculated in case-control 
studies [40,41]. The odds of being exposed among cases or controls are calculated by 
dividing the number of exposed cases or controls by the number of non-exposed cases 
(a/c) or controls (b/d), respectively. ORs are derived by dividing the odds of being exposed 
among cases by the odds of being exposed among controls ((a/c)/(b/d))=ad/bc. 
If the exposure variable is continuous, one option would be to categorise the variable and 
calculate ORs from the extended contingency table. Another option would be to compare 
means of the continuous exposure variable among the case and the control group. 
Continuous variables can also be included in regression models together with binary or 
categorical variables (see 3.2).  
1.1.5 Diagnostic performance and predictive ability 
In epidemiology, diagnostic performance of a test or predictive ability of a model can be 
evaluated by obtaining the following characteristics: sensitivity, specificity, negative 
predictive value (NPV) and positive predictive value (PPV) [42,43]. Sensitivity is the 
proportion of the persons with the outcome in the study population correctly identified as 
having the outcome (a/(a+c)). Specificity is defined as the proportion of subjects without 
the outcome in the study population correctly identified as not having the outcome 
(d/(d+b)). Sensitivity and specificity are not influenced by the prevalence of the outcome. 
The receiver operating characteristic (ROC) curve represents the diagnostic accuracy of a 
test or predictive ability of a model [44,45]. It is defined by sensitivity over 1-specificity 
(Figure 1.1-4). Or in other words, it is presented by the true positive rate over the false 
positive rate. The higher is the area under the ROC curve (AUC); the better is the test or 
model. If the AUC of the ROC curve has a value of 0.5, the discrimination of the test or 
model is no better than chance.  
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Figure 1.1-4: Receiver operating characteristic curve 
Line A represents an area under the 
curve (AUC) of 1, which would indicate 
the highest diagnostic accuracy or 
predictive ability. The discriminating line 
C (AUC = 0.5) corresponds to a 
discriminative ability of random chance. 
B (AUC = 0.75) represents a good 
receiver operating characteristic curve. 
Source: Zou KH et al. Circulation. 
2007;115:654-657 
 
 
 
 
 
While sensitivity and specificity describe the overall characteristics of a test, the NPV and 
the PPV describe how a test or model works under specific circumstances or in a specific 
patient [43]. The NPV is the probability that subjects with a negative test result or classified 
as low risk by the model do not have the outcome (d/(c+d)) and the PPV is the probability 
that subjects with a positive test result or classified as high risk by the model have the 
outcome (a/(a+b)). These measures are influenced by the prevalence of the disease.  
1.1.6 Analysis of epidemiological data 
In an earlier section, bias [30] and confounding [31] were discussed. To avoid bias, a 
careful study design is important, because bias can usually not be addressed during data 
analysis. However, there are several options to control for confounding during data 
analysis such as stratification, restriction, matching, use of propensity score or 
multivariable regression analysis [46-50].  
When the study population includes e.g. only male patients with the age between 50 and 
60 years, restriction was applied [46]. This may limit generalisability of the results. Matching 
refers to the procedure whereby one or more controls are selected for each case on the 
basis of specific criteria such as age, gender, and other important potential confounders 
[47]. Potential confounders should then be equally distributed among groups. Rosenbaum 
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et al. defined the propensity score as the conditional probability of treatment or exposure  
given all confounders [48]. Even unmeasured confounders can be considered with 
propensity scores [49]. Stratification is an effective and straightforward way to control for 
confounding. It means that the data on exposure and outcome are presented by categories 
of one or more potential confounding variables and exposure-specific outcome measures 
can be presented [50]. Univariable analysis is a powerful method to initially screen the data 
or if only a few confounders need to be controlled for. Nevertheless, if we want to control 
for several confounders at the same time, multivariable regression analysis is the preferred 
option (see 3.2). Propensity scores can be included in multivariable regression analysis.  
1.2 The burden of cancer 
Diseases in which the control mechanisms during cell division are impaired are called 
cancers or malignant tumours [51]. Benign tumours do not spread to other parts of the 
body, whereas malignant tumours can invade every tissue of the body via the blood and 
lymph systems and cause metastases [51].  
Cancers are usually named after the tissue they originate in. The following classification is 
suggested to divide main categories of cancer: carcinomas such as breast cancer, lung 
cancer and prostate cancer are cancers that derive from epithelial cells or tissues from 
internal organs; sarcomas are cancer cells that originate in connective or supportive tissue; 
myelomas are cancers of the bone marrow; lymphomas such as non-Hodgkin lymphoma 
(NHL) and Hodgkin lymphoma (HL) originate in lymphatic tissue and leukaemias such as 
acute myelogenous leukaemia or chronic lymphocytic leukaemia (CLL) originate in tissue 
that produces blood cells [52]. However, in the future cancers may no longer be classified 
according to the tissue of origin, but according to the common present genetic mutation or 
tumour biomarker [53,54]. This approach is already applied for cancer treatment as genetic 
mutations and tumour biomarkers can determine the response to treatment [55]. 
About 30% of all cancer deaths are caused by preventable risk factors such as obesity, 
unhealthy diet, lack of physical activity, smoking and alcohol consumption [56]. In low- and 
middle-income countries, cancers that are caused by viral infections with hepatitis B and 
C virus or human papilloma virus are responsible for up to 20% of cancer deaths. About 
60% of the new annual cancer cases occur in low- and middle-income countries of Africa, 
Asia, Central and South America [56]. 
In Europe, the age-adjusted incidence of common cancers such as colon, prostate, breast 
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and stomach cancer has slightly increased over the past two decades [57]. Although 
cancer mortality in high-income countries including Europe and the USA is declining 
[58,59], probably due to an earlier detection and better management of cancer, it still 
remains a leading cause of morbidity and mortality in Europe [58]. The Global Burden of 
Disease Study was initiated at the request of the World Bank and uses registration data 
and population-based study data sources to estimate worldwide and regional burden of 
disease in collaboration with the World Health Organization (WHO) [60]. It showed that 
global disability-adjusted life years in breast cancer and leukaemia were 174 per 100,000 
population and 139 per 100,000 population in the year 2010, respectively [61]. Age-
standardised mortality rates were 6.6 per 100,000 with breast cancer and 4.2 per 100,000 
subjects with leukaemia [62].  
1.2.1 Chronic lymphocytic leukaemia 
CLL is a subtype of NHLs. It is the most common leukaemia in adults and constitutes 
approximately 1% of all cancers [63]. CLL is a blood cancer, which is characterised by the 
abnormal accumulation of B-cell lymphocytes in the bone marrow and blood [64]. B-cell 
lymphocytes belong to the white blood cells and play an important role for the immune 
system by recognising antigens and producing antibodies [65].  
CLL is not a childhood disease and is very uncommon in young people. It becomes more 
common with older age, which is reflected by the average age at diagnosis of 72 years, 
and is more likely among men than women [66]. The estimated incidences for the USA 
and Europe range from 3-5 per 100,000 population or 100,000 person-years [66,67] and 
were determined before the year 2010. 
CLL is clinically heterogeneous. The characterisation of CLL ranges from a slowly 
developing, asymptomatic lymphocytosis to a progressive disease with enlarged lymph 
nodes, splenomegaly, anaemia, and thrombocytopenia [68]. The majority of CLL patients, 
about 70%, have an asymptomatic, slowly progressing form with a long survival [63]. 
Because these patients feel well, they may get diagnosed with CLL after a visit to the 
general practitioner (GP), where blood samples have been taken for a routine check-up. 
Those patients usually do not require immediate treatment [64]. Others present with an 
aggressive, symptomatic leukaemia where immediate treatment is required to postpone 
further progression of the disease [64]. 
With standard chemotherapy CLL remains incurable. Treatment is palliative and should be 
delayed until diseased patients are symptomatic [69]. Combination chemotherapy with 
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fludarabine, cyclophosphamide and rituximab is considered as a standard for fit, 
chemotherapy naive patients [70]. Elderly or comorbid patients can be treated with 
chlorambucil or bendamustine [71]. In patients who do not respond to 
chemoimmunotherapy or have high-risk CLL, allogeneic hematopoietic stem cell 
transplantation has been considered a treatment option [72]. Those patients need to be 
healthy apart from CLL because the risks of a transplant in elderly and comorbid patients 
are not acceptable [73]. New emerging treatments such as the antibody obinutuzumab, the 
kinase inhibitor idelalisib, or the immunomodulator lenalidomide might be more tolerable 
treatment strategies in the future [74]. 
Several prognostic markers such as age, stage, performance status, lymphocyte count, 
serum parameters and chromosomal abnormalities have been identified [64]. For example, 
the expression of the ZAP-70 marker has been associated with a shorter time period until 
treatment is applied and a reduced overall survival (OS) [75]. Generally, survival of CLL 
patients ranges from less than 2 to more than 15 years and overall median survival is 
approximately 10 years [63]. Neutropenia and infections due to chemotherapy remain a 
major cause of morbidity and mortality in CLL [76].  
1.2.2 Breast cancer 
In the USA, one in eight women over their lifetime is affected by breast cancer which is the 
most common invasive cancer in women [77]. Breast cancer develops from breast tissue 
and can manifest as a lump in the breast, change in the shape of the breast, or other skin 
changes around the breast. It can also build metastases and grow into other tissues.   
Incidence of breast cancer in Europe has been stable over the last 10 years or increased 
slightly due to implementation of breast cancer screening [57]. Other factors that 
contributed to the increase in breast cancer incidence are a change in lifestyle factors that 
are known to be associated with the risk of breast cancer and to a smaller extent genetic 
factors [78]. In Europe, the age-standardised incidence of breast cancer in 2008 was 70.7 
per 100,000 women [79]. 
Causes of breast cancer are unknown. Several risk factors have been identified in breast 
cancer such as gender, age, family history, hormonal factors, genetic factors and lifestyle 
factors [80]. Male breast cancer accounts for approximately 1% of all breast cancers [81]. 
Most risk factors that have been identified for breast cancer in women are also applicable 
to breast cancer in men [82].  
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Treatment options for breast cancer are: treatment of local disease with surgery or 
radiation, and treatment of systemic disease with hormonal therapy, chemotherapy or 
immunochemotherapy, or a combination of these treatment options [83]. The need for 
treatment and selection of treatment option is based on patient age [84], hormone receptor 
status [85], tumour histology and pathology [86], human epidermal growth factor receptor 
2 (HER2) status, and patient comorbid conditions [83].  
An indication for the prognosis of a patient with breast cancer is the TNM classification 
system; tumour size (T), nodes (N), and metastasis (M) [87]. The higher the tumour size 
and the more nodes involved, the less favourable is the prognosis. Patients with 
metastases have end-stage breast cancer. Two prognostic biomarkers such as estrogen 
receptor (ER) and HER2 are assessed routinely in every breast cancer to select patients 
benefitting from endocrine and HER2-targeted therapy [88]. Five-year disease-free 
survival rates differ according to breast cancer subtype and are about 93% in luminal A 
breast cancer and 78% in HER2-like breast cancer [89].  
In breast cancer patients receiving chemotherapy, neutropenia is less common than in 
haematological cancer patients undergoing chemotherapy. But high neutropenia rates in 
breast cancer patients receiving a specific chemotherapy have been reported and can be 
reduced by using prophylactic granulocyte colony-stimulating factors (G-CSFs) [90]. 
1.3 Chemotherapy-induced and febrile neutropenia in cancer patients 
Neutrophils belong to the white blood cells and are produced by haematopoietic stem cells 
(Figure 1.3-1). They form an important part of the innate immune system, because these 
are one of the first cells that enter the site of inflammation and release cytokines that 
amplify inflammatory reactions by other cell types  [91].  
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Figure 1.3-1: Haematopoiesis 
 
All blood cells develop and differentiate from pluripotent stem cells of the red bone marrow.  
Source: Figure adapted from "Hematopoiesis simple" by Mikael Häggström (no attribution required), from original by A. 
Rad (requires attribution) - Image:Hematopoiesis_(human)_diagram.png by A. Rad. Licensed under Creative Commons 
Attribution-Share Alike 3.0 via Wikimedia Commons  
http://commons.wikimedia.org/wiki/File:Hematopoiesis_simple.svg#mediaviewer/File:Hematopoiesis_simple.svg 
Neutropenia is defined as an absolute neutrophil count (ANC) lower than 1.5x109/L and 
classified according to the severity of the reduction of the ANC [92]. An ANC less than 
0.5x109/L is defined as severe or grade 4 neutropenia, an ANC between 0.5x109/L and 
1.0x109/L is defined as moderate neutropenia, and an ANC between 1.0x109/L and 
1.5x109/L is defined as mild neutropenia. Chemotherapy-induced neutropenia (CIN) and 
febrile neutropenia (FN) are frequent complications in cancer patients undergoing 
chemotherapy [93]. FN is defined as an ANC lower than 0.5x109/L with a concomitant oral 
temperature of 38° Celsius or more for more than 1 hour [94].  
High rates of CIN, FN and infectious complications are observed in CLL, NHL and breast 
cancer patients receiving standard of care chemotherapy [90,95-98]. CIN and FN not only 
remain the principal dose-limiting toxicities for cancer chemotherapy [99], they may also 
affect short- and long-term outcomes. Patients experiencing neutropenic events are more 
susceptible to subsequent infections due to a low neutrophil count [99,100]. Chemotherapy 
dose reductions or delays and hospitalisations due to CIN or FN impact on treatment 
success and short-term mortality [101-103].  
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1.3.1 Risk factors 
Risk factors of CIN or FN can be identified by performing univariable and multivariable 
regression analysis of collected data assessing the association between CIN or FN and 
different exposure variables.  
Numerous risk factors in different types of cancer have been reported to increase the risk 
of FN. Those included patient-related, tumour-related and chemotherapy-related factors 
and were identified in univariable and multivariable analysis (controlling for confounders). 
Older age, lower weight, prior chemotherapy, higher planned dose of chemotherapy, 
higher number of planned chemotherapy cycles, higher chemotherapy intensity, vascular 
comorbidity, lower baseline with blood cell (WBC) and red blood cell (RBC) count, lower 
platelet and neutrophil count, and higher baseline bilirubin, low serum albumin or 
haemoglobin, anaemia, increased lactate dehydrogenase or alkaline phosphatase, 
abnormal liver or renal function, poor performance status, low lymphocyte count, tumour 
stage, and lack of G-CSF prophylaxis were shown to be associated with an increased risk 
of FN [104-120]. 
Chemotherapy dose delays and dose reductions before CIN or FN occurred, higher weight, 
and prophylaxis with antibiotics or G-CSFs have been reported to be protective factors 
[105,106,110,111,115]. 
More recently, genetic factors such as certain genotypes in GSTP1 (Glutathione S-
transferase P1), UGT1A1 (UDP glucuronosyltransferase 1A1), MBL2 (Mannose-binding 
lectin), ABCC1/MRP1 (multidrug resistance-associated protein), UGT2B7 (UDP 
glucuronosyltransferase 2B7) and FGFR4 (fibroblast growth factor receptor 4) were shown 
to be significant predictors of FN in various tumour types [110,121-126]. 
1.3.2 Prediction models 
The underlying analysis to determine risk factors or to develop risk prediction models is the 
same. For the development of a risk prediction model, as many identified risk factors as 
possible should be considered. 
Risk models for the occurrence of CIN [106] and FN in breast cancer [104,127] and NHL 
patients [105] including patient- or chemotherapy-related factors have been published and 
were reported to be predictive. Other neutropenia risk models in different cancers have 
been proposed [113,128-131]. Risk factors that were reported in most studies were low  
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WBC count, planned cycles of chemotherapy, and higher intensity of chemotherapy. 
Several risk prediction models assessed model performance by reporting test 
characteristics and ROC curves [105,106,113,127,130]. Ranges were 24% - 90% for 
sensitivity, 59% - 93% for specificity, 84% - 97% for NPV, 12% - 59% for PPV, and 0.74 - 
0.86 for area under the ROC curve [105,106,113,127,130,131]. All models had in common 
that they were predictive of the outcome to a certain extent, but the PPV remained low. 
Further refinement of these models is necessary. 
Different approaches for internal validation such as split-sample validation, cross-
validation, and bootstrapping are available [132]. Hosmer et al. and Lyman et al. [113,130] 
split their population sample into a training dataset, where the model was developed and 
a validation dataset, where the developed model was applied to. Pettengell et al. and 
Schwenkglenks et al. used 10-fold cross validation [105,106]. The advantage of 10-fold 
cross validation is that the entire sample is used to either develop or validate the model. 
The dataset is randomly split into 10 subsamples and the model is developed in 9 datasets 
and validated in the remaining dataset [133]. This procedure will be repeated for each 
subsample [133]. Dranitsaris et al. used bootstrapping techniques to show that the 
resampled bootstrap regression coefficients and confidence intervals (CIs) were similar to 
the regression coefficients and CIs obtained from the model [127,132]. Predictive ability of 
all models during split-sample validation and cross-validation was slightly lower than in the 
apparent dataset. 
Before risk prediction models can be applied in clinical practice they should undergo 
external validation [134]. Jenkins et al. performed a partial validation of their original model 
[104] using an independent dataset [108]. In addition, the Jenkins’ model [104] was 
externally validated by other researchers, who concluded that the Jenkins’ model cannot 
accurately identify patients at high risk of FN, but no successful validation criteria were pre-
defined [135].  
1.4 Granulocyte colony-stimulating factors 
Natural human G-CSF is a bone marrow-stimulating hormonal glycoprotein that induces 
the proliferation and differentiation of pre-mature granulocytes and other haematopoietic 
stem cells [136]. Granulocyte macrophage colony-stimulating factors have haematopoietic 
activity, but are reported to be less efficient than G-CSFs [137]. Natural G-CSFs are 
produced by several cells of the immune system [136].  
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Pharmaceutical analogues of naturally occurring G-CSFs called recombinant human G-
CSFs such as filgrastim and pegfilgrastim have been developed [138,139]. They have 
been shown to stimulate the production and differentiation of neutrophils. Two main groups 
of G-CSFs can be differentiated: short-acting G-CSFs such as filgrastim, lenograstim, and 
sargramostim and long-acting G-CSFs such as pegfilgrastim, lipegfilgrastim and 
balugrastim [140]. Daily G-CSFs are primarily cleared through the kidneys and require daily 
dosing until recovery of the neutrophil count. Long-acting G-CSFs are primarily cleared by 
neutrophils and have significantly reduced renal clearance compared with daily G-CSFs. 
They therefore require only a single dose per chemotherapy cycle. 
G-CSFs have been shown to reduce the incidence and duration of CIN and FN [140]. 
According to the European Organisation for Research and Treatment of Cancer (EORTC) 
and other international guidelines, prophylactic G-CSF use is recommended if the 
underlying risk of FN of the planned chemotherapy regimen is 20% or higher [98,141-143]. 
For chemotherapy regimens with an intermediate FN risk (10-20%), the EORTC guideline 
recommends that patient risk factors should be taken into account when the individual risk 
of FN and the likely benefit of G-CSF support is determined [98]. For patients with 
prolonged neutropenia or other risk factors favouring neutropenia-related complications, 
antibacterial and antifungal prophylaxis have recently been recommended [144]. But 
issues with resistance need to be considered.
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2 Objectives of the thesis 
The overall aim of this thesis was to contribute to the knowledge of CLL epidemiology and 
CIN or FN occurrence in cancer patients, and to promote the development and validation 
of risk prediction models for FN to optimally target G-CSF prophylaxis in cancer patients 
undergoing chemotherapy. Following research questions were defined for the four 
subsequent studies. 
The aim of the first study was to assess incidence rates of CLL between the years 2000 
and 2012 and to evaluate time trends in CLL incidence. Another aim of the study was to 
describe medical resource utilisation in CLL patients and to derive changes over time. 
In the second study, the author aimed to describe the occurrence of FN in breast cancer 
patients in the first and any cycle of chemotherapy. Based on a large set of patient-related, 
chemotherapy-related, tumour-related factors as well as genetic characteristics, a risk 
prediction model for the occurrence of FN was developed. 
The research question of the third study was to externally validate the predictive ability of 
a risk prediction model for FN in NHL patients developed by the Impact of Neutropenia in 
Chemotherapy-European Study Group (INC-EU) using an independent NHL dataset.  
By conducting a systematic literature review, the fourth study summarised the available 
evidence on the efficacy, effectiveness and safety of long-acting G-CSFs for prophylaxis 
of CIN and FN in adult cancer patients undergoing chemotherapy. 
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3 Methods 
The studies which form the basis of this work were conducted using different data sources. 
For the first study, a physician-based large healthcare database was used, which contains 
electronically recorded patient data about demographics, diagnoses, healthcare visits and 
prescriptions (4.1). The second analysis was conducted using a hospital-based database, 
which followed a cohort of a pre-defined population over a certain time period and collected 
data about several exposures (4.2). For the third analysis, collected data from two 
independent prospective observational studies looking at a specific outcome were 
evaluated (4.3). In the last study, electronic databases of published literature were used to 
search for studies on specific drugs (4.4). Details of the data sources are described in the 
sections 4.1 - 4.4 and are provided for each study separately.  
Different methodological approaches were used. Qualitative methods for data collection 
and data analysis such as systematic literature reviews were combined with descriptive 
and quantitative methods such as univariable and multivariable regression analysis. The 
general principles of the methods applied are described in the following sections. Details 
of the methodological approaches are reported in the results’ sections 4.1 - 4.4 and 
according to the studies. 
3.1 Descriptive and univariable analyses 
The aim of descriptive analysis was to provide an overview of the data and population 
studied. A common way is to provide tables that contain quantitative information about the 
most important exposure and/or outcome variables. Basic descriptive statistics that were 
used in the studies included the number of observations (N for total number of e.g. subjects 
or participants included, n for the number of observations); mean and standard deviation 
(SD) for normally distributed numerical and continuous variables; median, quartiles and 
range for numerical and continuous variables with a skewed distribution; and frequencies 
and percentages for binary (e.g. yes or no), categorical (e.g. blue, green, or red) or ordered 
variables (e.g. mild, moderate, severe). These data can be graphically represented by e.g. 
histograms or boxplots (Figure 3.1-1).  
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Figure 3.1-1: Histogram and corresponding boxplot 
A histogram (dark 
grey) represents the 
probability distribution 
of a continuous 
variable. A boxplot 
indicates the median 
(black) and the 
spread of the data 
(light grey).  
 
 
 
 
 
Univariable analysis is appropriate to measure the association between the outcome and 
one exposure variable at the time. For binary or categorical data, a chi-squared test was 
performed. The chi-squared test assessed if there is a difference in two or more proportions 
[145]. If sample sizes would have been small, Fisher’s exact test would have been used 
instead. Linear correlations between exposure variables were assessed using Pearson’s 
correlation coefficient and monotonic correlations were assessed using Spearman’s 
correlation coefficient. Univariable logistic regression was performed to evaluate 
associations between the outcome and continuous variables and effect measures (e.g. 
ORs and 95% CIs) and p-values were obtained.  
3.2 Multivariable regression analysis 
Multivariable regression analysis is a powerful technique to describe the association 
between the outcome variable and several exposure variables or to predict the outcome 
based on the exposure variables. Depending on the aim of the regression model, different 
model development approaches are recommended. To determine factors that could 
predict the outcome, as many variables as necessary to get a reliable prediction model 
should be included. For a potentially causal model, only those factors with a specific 
hypothesis for a relationship with the outcome should be included. Drawing a DAG 
beforehand can help to identify those factors. The choice of regression analysis depended 
on the type of outcome variable that was assessed and its underlying distribution. For 
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example, linear regression analysis is used when the outcome variable is continuous [146].  
𝑌𝑌 (𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜) =  𝛼𝛼 (𝑖𝑖𝑖𝑖𝑜𝑜𝑜𝑜𝑖𝑖𝑜𝑜𝑜𝑜𝑖𝑖𝑜𝑜) +  𝛽𝛽(𝑖𝑖𝑜𝑜𝑟𝑟𝑖𝑖𝑜𝑜𝑟𝑟𝑟𝑟𝑖𝑖𝑜𝑜𝑖𝑖 𝑜𝑜𝑜𝑜𝑜𝑜𝑒𝑒𝑒𝑒𝑖𝑖𝑜𝑜𝑖𝑖𝑜𝑜𝑖𝑖𝑜𝑜) ∗ 𝑋𝑋 (𝑜𝑜𝑒𝑒𝑖𝑖𝑜𝑜𝑟𝑟𝑜𝑜𝑖𝑖𝑜𝑜 𝑣𝑣𝑣𝑣𝑖𝑖𝑖𝑖𝑣𝑣𝑣𝑣𝑣𝑣𝑜𝑜) 
Other regression analyses such as logistic regression, Poisson regression, and Cox 
proportional hazard regression applied in the studies this work is based on are described 
in the following sections. 
3.2.1 Multivariable logistic regression 
The use of logistic regression analysis is appropriate when the outcome variable is binary 
(e.g. yes or no) [147]. In logistic regression, the proportion of the outcome variable Y is 
assessed given the exposure variable X. Because proportions range from 0 to 1, but the 
predicted values in standard multiple regression can take any negative or positive value, it 
is necessary to transform the outcome variable. The proportion of the outcome is 
transformed into odds (proportion [p]/1-proportion [1-p]) and we take the log of the odds 
which is called logit transformation.  
log ( 𝑖𝑖1 − 𝑖𝑖) =  𝛼𝛼 (𝑖𝑖𝑖𝑖𝑜𝑜𝑜𝑜𝑖𝑖𝑜𝑜𝑜𝑜𝑖𝑖𝑜𝑜) +  𝛽𝛽(𝑖𝑖𝑜𝑜𝑟𝑟𝑖𝑖𝑜𝑜𝑟𝑟𝑟𝑟𝑖𝑖𝑜𝑜𝑖𝑖 𝑜𝑜𝑜𝑜𝑜𝑜𝑒𝑒𝑒𝑒𝑖𝑖𝑜𝑜𝑖𝑖𝑜𝑜𝑖𝑖𝑜𝑜) ∗ 𝑋𝑋 (𝑜𝑜𝑒𝑒𝑖𝑖𝑜𝑜𝑟𝑟𝑜𝑜𝑖𝑖𝑜𝑜 𝑣𝑣𝑣𝑣𝑖𝑖𝑖𝑖𝑣𝑣𝑣𝑣𝑣𝑣𝑜𝑜) 
For the logistic model, the maximum likelihood method provides estimates of the 
regression coefficients (α, β) which maximise the likelihood of obtaining the data that were 
observed. 
As the logistic regression model was fitted using the logit transformation, the regression 
coefficients need to be exponentiated before being interpreted. When we exponentiate the 
regression coefficient β, we obtain the OR of occurrence of the outcome for a one unit 
increase of the exposure variable (continuous) or the OR for a certain group compared to 
the reference group (binary or categorical variable).  
To test whether the logistic regression model including the exposure variable fits the data 
better than the model without the exposure variable, a likelihood ratio test can be obtained. 
If the likelihood ratio test reports a p-value<0.05, it means that the exposure variable would 
usually be included in the model.  
The same rules apply to multivariable logistic regression. Instead of only one exposure 
variable, several exposure and confounding variables can be included in the model.  
log ( 𝑖𝑖1 − 𝑖𝑖) =  𝛼𝛼 +  𝛽𝛽1 ∗ 𝑋𝑋1 +  𝛽𝛽2 ∗ 𝑋𝑋2 + ⋯+  𝛽𝛽𝑖𝑖 ∗ 𝑋𝑋𝑖𝑖 
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The interpretation of the OR is the same, except that the resulting OR is adjusted for other 
exposure variables and confounding variables. 
3.2.2 Poisson regression 
Poisson regression is used if the outcome variable describes counts or rates, which are 
distributed at random and independent of each other [148]. The analysis of counts with 
Poisson regression shares common features with the logistic regression. As with the 
logistic regression, the right part of the equation can take more values than the left part of 
the equation. Therefore, the left part of the model is log-transformed. This kind of Poisson 
regression model is called log-linear model. log(𝑌𝑌) =  𝛼𝛼 + 𝛽𝛽 ∗ 𝑋𝑋 which is equivalent to 𝑌𝑌 = exp (𝛼𝛼 + 𝛽𝛽 ∗ 𝑋𝑋)  
The regression coefficients of the Poisson regression are calculated using again the 
maximum likelihood method. Because of the log transformation, the resulting regression 
coefficients need to be exponentiated for interpretation. The exponentiated regression 
coefficient α estimates the mean of the outcome variable when the exposure variable is 
zero. With every one unit increase of the exposure variable, the outcome is multiplied by 
the exponentiated regression coefficient β. To test if the exposure variable should be 
included in the model or not, the likelihood ratio test can be applied.  
Rates such as incidence rates or mortality rates are analysed using Poisson regression as 
well. In addition to counts, rates also take into account follow-up time or the period of 
exposure and are defined as number of counts (N) divided by the time period (T). Using 
again the log transformation, the Poisson regression takes the following form:  
log(𝑅𝑅) = log �𝑁𝑁
𝑇𝑇
� =𝛼𝛼 + 𝛽𝛽 ∗ 𝑋𝑋 which is equivalent to  log(𝑁𝑁) = log(𝑇𝑇) + 𝛼𝛼 + 𝛽𝛽 ∗ 𝑋𝑋 
The offset is the log of the time period, which is considered as a variable in the Poisson 
regression with a fixed regression coefficient 1. By exponentiating the regression 
coefficient it can be interpreted as rate ratio or IRR for a one unit increase of the exposure 
variable or the rate ratio or IRR for a certain category compared to the reference category.  
3.2.3 Cox proportional hazard regression 
Cox proportional hazard regression is applied when analysing time-to-event or survival 
data [149]. Survival is a function of time: it is 1 at the time point 0 and it goes to 0 as time 
goes to infinity. The hazard function h(t) is the instantaneous rate at which events occur 
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given no previous events. The cumulative hazard H(t) describes the accumulated hazard 
up to time t.  
Survival can be estimated by using the non-parametric Kaplan Meier estimator (Figure 
3.2-1). At every time point, the Kaplan Meier estimator calculates the number of subjects 
still at risk, the number of subjects that had the outcome, and the number of subjects that 
have been censored. From these numbers, the Kaplan Meier approach can estimate the 
probability of survival and the survival function. But the Kaplan Meier curve is not suitable 
for the evaluation of the impact of several exposures on survival. 
Figure 3.2-1: Kaplan-Meier estimate of survival 
Kaplan Meier curve 
presenting survival 
curves for a non-
exposed group (line 
above) and an 
exposed group (line 
below). Median 
survival is 7.6 years 
for the exposed group 
and 10 years for the 
non-exposed group. 
 
 
 
 
 
The most commonly used regression for survival data is the Cox proportional hazards 
regression. The Cox proportional hazard model assumes that without interaction, the 
exposures and confounders add to the baseline hazard and the effect of the exposures 
does not change over time. The regression takes the form: 
ℎ(𝑜𝑜|𝑋𝑋) = ℎ(𝑜𝑜)(baseline hazard) ∗ exp(𝛼𝛼 + 𝛽𝛽 ∗ 𝑋𝑋)  (effect of exposures) 
which is equivalent to log�ℎ(𝑜𝑜|𝑋𝑋)� = log�ℎ(𝑜𝑜)� + (𝛼𝛼 + 𝛽𝛽 ∗ 𝑋𝑋)  
By exponentiating the regression coefficient it can be interpreted as hazard ratio (HR). For 
every one unit increase of the exposure variable, the hazard of the event increases by the 
factor of the HR at all points in time.  
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3.3 Systematic literature review 
A systematic literature review aims to summarise the available evidence regarding a 
specific topic of interest. It aims to provide an objective appraisal of the evidence. In 
comparison to narrative literature reviews, it follows a systematic approach to minimise 
bias and random errors. This means that a systematic review should always include a 
materials and methods’ section. Guidelines on the conduct of systematic reviews have 
been published (Table 3.3-1) [150,151]. 
Before conducting a systematic literature review, a study question needs to be formulated 
according to the PICOS (P-who is the patient/participant, I-what is the intervention or 
exposure, C-what is the comparison group, O-what is the outcome or endpoint, S-what is 
the study design) criteria, which are an expansion of the PICO criteria [152]. 
After the study question has been defined, a search strategy needs to be developed 
considering as much literature sources as appropriate including e.g. MEDLINE, EMBASE, 
the Cochrane Library, the Centre for Review and Dissemination databases, the Cochrane 
Central Register of Controlled Trials, other trial registers, manual searches of key journals 
and abstract books. Keywords or search terms need to be defined that are used to search 
the databases. Eligibility criteria have to be defined beforehand to decide which of the 
studies will be included in the systematic literature review. Study selection and data 
extraction should be performed by two independent researchers, if possible. For the 
analysis and interpretation of the results, a risk of bias assessment of the included studies 
is recommended to consider limitations, biases, strength of the evidence and applicability. 
Finally, the results of the systematic literature review should be published.  
Although the primary analysis of systematic literature reviews is of qualitative nature, there 
is a method called meta-analysis that quantitatively summarises the data obtained from a 
systematic literature review. However, if the included studies are very heterogeneous, 
guidelines do not recommend performing meta-analysis [153]. 
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Table 3.3-1: PRISMA 2009 Checklist [151] 
Section/topic  # Checklist item  Reported 
on page 
#  
TITLE 1 Identify the report as a systematic review, meta-analysis, or both.   
ABSTRACT 
Structured 
summary  
2 Provide a structured summary including, as applicable: background; 
objectives; data sources; study eligibility criteria, participants, and 
interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic 
review registration number.  
 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is 
already known.  
 
Objectives  4 Provide an explicit statement of questions being addressed with 
reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS).  
 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed 
(e.g., Web address), and, if available, provide registration 
information including registration number.  
 
Eligibility 
criteria  
6 Specify study characteristics (e.g., PICOS, length of follow-up) and 
report characteristics (e.g., years considered, language, publication 
status) used as criteria for eligibility, giving rationale.  
 
Information 
sources  
7 Describe all information sources (e.g., databases with dates of 
coverage, contact with study authors to identify additional studies) 
in the search and date last searched.  
 
Search  8 Present full electronic search strategy for at least one database, 
including any limits used, such that it could be repeated.  
 
Study 
selection  
9 State the process for selecting studies (i.e., screening, eligibility, 
included in systematic review, and, if applicable, included in the 
meta-analysis).  
 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted 
forms, independently, in duplicate) and any processes for obtaining 
and confirming data from investigators.  
 
Data items  11 List and define all variables for which data were sought (e.g., PICOS) 
and any assumptions that were made. 
 
Risk of bias in 
individual 
studies  
12 Describe methods used for assessing risk of bias of individual 
studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in 
any data synthesis.  
 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, difference in 
means).  
 
Synthesis of 
results  
14 Describe the methods of handling data and combining results of 
studies, if done, including measures of consistency (e.g., I2) for each 
meta-analysis.  
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Section/topic  # Checklist item  Reported 
on page #  
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias).  
 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or 
subgroup analyses, meta-regression), if done, indicating which were 
pre-specified.  
 
RESULTS   
Study 
selection  
17 Give numbers of studies screened, assessed for eligibility, and 
included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram.  
 
Study 
characteristics  
18 For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and provide the 
citations.  
 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, any 
outcome level assessment (see 12).  
 
Results of 
individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each 
study: (a) simple summary data for each intervention group (b) 
effect estimates and confidence intervals, ideally with a forest plot.  
 
Synthesis of 
results  
21 Present results of each meta-analysis done, including confidence 
intervals and measures of consistency.  
 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across studies (see 
15).  
 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or 
subgroup analyses, meta-regression [see 16]).  
 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for 
each main outcome; consider their relevance to key groups (e.g., 
healthcare providers, users, and policy makers).  
 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), 
and at review-level (e.g., reporting bias).  
 
Conclusions  26 Provide a general interpretation of the results in the context of 
other evidence, and implications for future research.  
 
FUNDING   
Funding  27 Describe sources of funding and role of funders for the systematic 
review and other support 
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4 Published results 
According to the four studies that formed the basis for this thesis, the results’ section is 
divided into four parts (4.1 - 4.4). Each part corresponds to one peer-reviewed publication.  
4.1 Trends in incidence and medical resource utilisation in patients with chronic 
lymphocytic leukaemia: insights from the UK Clinical Practice Research 
Datalink (CPRD). Ann Hematol. 2014 [Epub ahead of print] 
4.2 Multivariable regression analysis of febrile neutropenia occurrence in early 
breast cancer patients receiving chemotherapy assessing patient-related, 
chemotherapy-related and genetic risk factors. BMC Cancer 2014; 14: 201 
4.3 External validation of a risk model of febrile neutropenia occurrence in patients 
with non-Hodgkin lymphoma. Leuk Lymphoma 2013; 54(11): 2426-2432 
4.4 Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating 
factors for prophylaxis of chemotherapy-induced neutropenia in patients with 
cancer: a systematic review. Support Care Cancer 2015; 23(2): 525-545 
For all publications, final drafts after refereeing are included below as permitted by the 
publishers’ copyright and self-archiving policies. Tables and figures have been numbered 
according to the section to maintain the numbering within a publication. Reference lists are 
provided for each peer-reviewed publication separately and a comprehensive list of 
references is provided at the end.  
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Abstract  
Background: Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in 
European adults. We aimed to evaluate time trends in CLL incidence and medical resource 
utilisation of CLL patients in the UK. 
Methods: We conducted a retrospective, observational cohort analysis using the UK 
Clinical Practice Research Datalink (CPRD) comprising mainly primary care data. We 
included adult patients with newly diagnosed CLL between January 2000 and June 2012. 
We performed descriptive and trend analyses of CLL incidence and medical resource 
utilisation.   
Results: A total of 2,576 patients with CLL met eligibility criteria. At diagnosis, the majority 
of patients (71.7%) were above 65 years of age. The European age-standardised CLL 
incidence rate in the CPRD was 6.2/100,000 (95% confidence interval [CI] 6.0, 
6.5/100,000) person-years. There was no statistically significant increase over time. The 
CLL patients had on average 74.6 general practitioner visits during a median follow-up of 
3.3 years.  Between 2000 to 2012, the average number of recorded hospitalisations and 
referrals per year corrected for duration of follow-up significantly (p<0.001) increased by 
8.1% (95% CI 6.8%, 9.3%) and 16.4% (95% CI 15.4%, 17.3%), respectively. Referrals and 
hospitalisations in the second year compared to the first year following the CLL diagnosis 
significantly decreased. 
Conclusion: CLL incidence rates in the CPRD were stable over the period from 2000 to 
2012. Medical resource utilisation in UK primary care was well documented, but further 
research is needed to describe secondary and tertiary care medical resource utilisation, 
e.g. chemotherapy.  
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Introduction 
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in adults. The clinical 
manifestations of CLL range from an asymptomatic presentation with minimal B-cell 
lymphocytosis to a progressive clinical picture of enlarged lymph nodes, splenomegaly, 
anaemia, and thrombocytopenia [68]. Median age at diagnosis has been reported to be 72 
years [66] and males are more likely to develop CLL than females. Several prognostic 
markers such as age, stage, performance status, lymphocyte count, serum parameters 
and chromosomal abnormalities have been identified [68]. Survival time of patients with 
CLL ranges from less than two years to 15 years or more with a median survival of about 
10 years [63]. In the US, CLL occurs with an estimated incidence of 3-5/100,000 people 
per year [66]. A crude incidence rate of 4.2/100,000 person-years has been reported for 
the UK in 2009 [67]. There are no current age-standardised incidence data for Europe.  
About 70% of patients with CLL are asymptomatic and at an early disease stage at the 
time of diagnosis [63]. Chemotherapy in CLL patients is not recommended until patients 
develop symptoms, have organ compromise or until the disease is rapidly progressing. 
Before initiating chemotherapy treatment, it is important to assess the fitness level of a CLL 
patient [154,155]. Depending on life expectancy, general health status and expected ability 
to tolerate aggressive chemotherapy, different chemotherapy regimens are used to treat 
CLL. Combination chemotherapy with fludarabine, cyclophosphamide and rituximab is 
considered as a standard for fit, chemotherapy naive patients [156] but may not always be 
suitable for elderly patients or those with comorbidities. Chlorambucil in combination with 
an anti-CD20 monoclonal antibody such as rituximab or obinutuzumab is considered 
standard for elderly or comorbid patients [157]. 
As a result, various management strategies are possible. Intensive immuno-chemotherapy 
is given to fit patients with no or mild comorbidities and normal life expectancy (Go-Go) 
aiming at achieving prolonged progression-free and overall survival. Symptom relief and 
response to treatment are the main goal in the intermediate chemotherapy intensity group 
with moderate comorbidities and compromised life expectancy (Slow-Go). In patients with 
several or severe comorbidities and very short life expectancy, symptom management and 
prolongation of functional independence (No-Go) are the main objectives [158]. Instead of 
starting with the least aggressive chemotherapy, followed if needed by a second, more 
aggressive treatment regimen, the optimal chemotherapy is given to patients upfront to  
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keep them in remission for as long as possible. The change in management of CLL patients 
from palliative to curative care and towards an individually-tailored chemotherapy [64,159], 
together with its impact on resource utilisation, are poorly studied.  
We aimed to assess CLL incidence rates and to evaluate time trends in CLL incidence and 
medical resource utilisation of CLL patients using a primary care database from the UK.  
Methods 
Study design and data source 
We conducted a retrospective, observational cohort study using the large, anonymised UK-
based Clinical Practice Research Datalink (CPRD). The CPRD, formerly known as the 
General Practice Research Database (GPRD), established in 1987, is part of the UK 
National Health Service’s (NHS) National Institute for Health Research (NIHR) and the 
Medicines and Healthcare Products Regulatory Agency (MHRA). The database contains 
primary care data on about 13% of the UK population and is representative of this 
population with respect to age, gender, regional distribution and annual turnover rate. 
General practicioners (GPs) are trained to record clinical data in a standardised manner. 
The MHRA anonymises the raw data before release and performs quality controls to 
ensure that the standards of the data collection are fulfilled. The database contains 
information on patient demographics such as age and gender, body mass index (BMI), 
region of residence, medical diagnoses, laboratory test results, information about referrals 
to specialists, hospitalisations, and drug prescriptions.  
This study was approved by the Independent Scientific Advisory Committee (ISAC) for 
MHRA database. Numerous studies involving cancer have been conducted using the 
CPRD [160-162], and the validity of the data recorded in the database has been reported 
to be high [163].  
Study population  
The study population consisted of patients with a diagnosis of CLL between January 2000 
and June 2012 aged 18 years or older at the time of diagnosis. Subjects with less than 
three years of recorded history prior to the CLL diagnosis were excluded in order to 
increase the likelihood of capturing truly incident cases. Patients diagnosed with CLL 
before 2000 were excluded because the degree of consistency of the recording of the CLL 
diagnosis and the medical resource utilisation in the CPRD before 2000 was unclear. We  
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validated the CLL diagnosis by screening 100 randomly selected CLL patient records for 
typical diagnostic procedures such as blood tests, chest X-rays, bone marrow 
examinations and ultrasound scans; for symptoms such as swollen lymph glands, fever, 
unusual sweating and tiredness; for referrals to a specialist or specialised clinic; and for 
prescriptions such as chlorambucil, fludarabine, cyclophosphamide and rituximab. The 
CLL diagnosis was considered validated if the 100 CLL patient profiles included at least 
one screening criterion for CLL.  
Follow-up and incidence rates 
We followed all patients in  the study population  from the date of CLL diagnosis until they 
died, left the practice, or reached the end of the study period. Incidence rates were 
calculated as the number of new cases divided by the total number of person-years at risk. 
We summarised person-years by year for all subjects enrolled in the CPRD with at least 
three years of prior history and at risk of CLL between 2000 and the end of follow-up (i.e. 
a CLL diagnosis, death, leaving the practice, or the end of the study period). Age-
standardised incidence rates were calculated based on the most recently updated 
European standard population [164].  
Basic characteristics and Charlson comorbidity weighted index 
For all patients in the study population, we assessed basic characteristics such as age at 
CLL diagnosis, gender, smoking status, alcohol consumption, BMI, body surface area 
(BSA), height and weight. For smoking status, alcohol consumption, BMI, BSA, height and 
weight the values recorded closest and prior to the CLL diagnosis date were extracted. 
Additionally, we extracted all comorbidities included in the Charlson comorbidity weighted 
index, because they were associated with the risk of mortality [165].  
Medical resource utilisation 
We assessed medical resource utilisation between the CLL diagnosis and the end of 
follow-up,  including number of GP visits, hospitalisations, referrals to specialists (such as 
oncologists, radiotherapists, or haematologists) or specialised clinics, number of cancer-
related therapies (such as chemotherapies or radiotherapies), blood transfusions, blood 
tests (such as red blood cell counts or neutrophil counts), and prescriptions for 
chemotherapeutics, antidepressants, antiemetics, antifungals, antibiotics, antivirals, 
immunosuppressants and growth factors.  
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Descriptive and statistical analysis 
We summarised categorical data using standard descriptive statistics, i.e. number of 
observations, frequencies and percentages. Continuous data were reported using the 
mean and standard deviation (SD) if normally distributed. Median and interquartile range 
(IQR) or range were reported if the distribution was skewed. We performed log-linear 
poisson regression to describe the change in age-adjusted incidence rate over time [166]. 
The age-specific inidence rates, expressed as the division of incident counts and 
corresponding person-years, were log-transformed. Person-years on the log scale were 
then added up and used in the model as an offset, a value that is known and not predicted 
by the regression. The offset was subsequently used to re-calculate the age-adjusted 
incidence rate from the estimated count.  
We performed multivariable Cox regression [149] to determine the influence of age at 
diagnosis, gender, Charlson comorbidity weighted index and year of diagnosis on overall 
survival. Analyses of time trends in medical resource utilisation were performed using 
poisson regression for count data. To correct for a possible cohort effect in the CPRD trend 
analyses of medical resource utilisation, years of follow-up were included in the Poisson 
regression model as an explanatory variable. 
We carried out two-sided statistical tests at a 5% significance level and 95% confidence 
intervals (CIs) were obtained, if applicable. All analyses were performed using Stata/SE 
version 12.1 (StataCorp LP, College Station, TX, USA). 
Results 
We identified 5,266 (0.05%) patients with a diagnosis of CLL from among around 9 million 
subjects currently included in the CPRD. Of these, 2,690 patients were excluded because 
they did not meet eligibility criteria. Figure 4.1-1 shows details of the patient selection. 
We included  2,576 patients with a diagnosis of CLL aged 18 years or older  in the analyses, 
of whom 1,498 (58.2%) were male and 1,078 (41.8%) were female. Mean age at diagnosis 
was 70.9 years (SD±11.3 years, range: 32-102 years); a majority of patients (n=1,847, 
71.7%) were of age 65 years or over. On average, CLL patients had 12.8 (SD 4.9) years 
of recorded prior history. Further characteristics of the study population are presented in 
Table 4.1-1. 
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Figure 4.1-1: Patient selection flow diagram 
 
Incidence rates 
The overall crude CLL incidence rate was 7.2/100,000 (95% CI 6.9, 7.4/100,000) person-
years, and the overall age-standardised incidence rate was 6.2/100,000 (95% CI 6.0, 
6.5/100,000) person-years. Age-standardised incidence rates in 2000 and 2010 were 
5.6/100,000 (95% CI 4.7, 6.4/100,000) person-years and 6.4/100,000 (95% CI 5.5, 
7.2/100,000) person-years, respectively (Figure 4.1-2). This corresponds to an average 
annual increase of 0.2%, which did not reach statistical significance (p=0.787). In some 
years, rates of up to 6.8/100,000 (95% CI 5.9, 7.7/100,000) person-years were seen. There 
was a decline in the age-standardised incidence rate in 2012. In the past five years, we 
observed a stabilisation of CLL incidence rates in the CPRD population. 
  
Total number of patients in the 
CPRD (at time of data extraction) 
n = 8,886,904 
Patients with a diagnosis of CLL  
n = 5,266 
Patients below the age of 18 (n=1), 
with less than three years of prior 
recorded history (n=743) and with a 
CLL diagnosis before the year 2000 
(n=1,946) were excluded 
Patients included in the study 
population 
n = 2,576 
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Table 4.1-1: Characteristics of the study population 
 Patients  
N = 2,576 % 
Age at diagnosis 
18-32 years 
32-62 years 
63-71 years 
72-78 years 
79+ years 
2,576 
0 
607 
672 
598 
699 
100.0 
0.0 
23.6 
26.1 
23.2 
27.1 
Gender 
Female 
Male 
2,576 
1,078 
1,498 
100.0 
41.8 
58.2 
Smoking status 
Non-smoker 
Current smoker 
Former smoker 
Unknown 
2,576 
1,156 
252 
1,053 
33 
100.0 
44.9 
9.8 
44.0 
1.3 
Alcohol consumption 
Never  
Current  
Former 
Unknown  
2,576 
439 
1,846 
65 
226 
100.0 
17.0 
71.7 
2.5 
8.8 
Body mass index (kg/m2) 26.6 ± 4.8* 2,388 92.7 
Body surface area (m2) 1.9 ± 0.2* 2,384 92.5 
 n  Men (%) Women (%) 
Comorbidities 
None 
COPD 
Congestive heart failure 
Myocardial infarction 
Hypertension 
Hypotension 
Diabetes 
Peripheral vascular disease 
Cerebrovascular disease 
Renal diseases 
Ulcer 
Liver disease 
Connective tissue disease 
Hemiplegia 
Dementia 
All tumours 
Metastatic solid tumour 
Lymphoma# 
Secondary malignancies§ 
 
1,529 
189 
95 
65 
406 
55 
215 
82 
73 
392 
187 
8 
3 
2 
60 
7 
7 
86 
127 
 
873 (33.9) 
136 (5.3) 
     64 (2.5) 
46 (1.8) 
221 (8.6) 
37 (1.4) 
127 (4.9) 
53 (2.1) 
44 (1.7) 
209 (8.1) 
105 (4.1) 
8 (0.3) 
3 (0.1) 
2 (0.0) 
28 (1.1) 
5 (0.2) 
5 (0.2) 
53 (2.1) 
84 (3.3) 
 
656 (25.5) 
53 (2.0) 
31 (1.2)  
19 (0.7) 
185 (7.2) 
18 (0.7) 
88 (3.4) 
29 (1.1) 
29 (1.1) 
183 (7.1) 
82 (3.2) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
32 (1.2) 
2 (0.0) 
2 (0.0) 
33 (1.3) 
43 (1.7) 
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 n Men (%) Women (%) 
Charlson comorbidity weighted index  
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
 
1,529 
424 
376 
151 
52 
18 
15 
4 
5 
2 
 
873 (33.9) 
255 (9.9) 
220 (8.5) 
91 (3.5) 
31 (1.2) 
12 (0.5) 
8 (0.3) 
3 (0.1) 
4 (0.2) 
1 (0.0) 
 
656 (25.5) 
169 (6.6) 
156 (6.1) 
60 (2.3) 
21 (0.8) 
6 (0.2) 
7 (0.3) 
1 (0.0) 
1 (0.0) 
1 (0.0) 
COPD, chronic obstructive pulmonary disease; n, number of patients; NOS, not otherwise specified 
* mean ± standard deviation 
% given as the percentage of the total number of patients (n=2,576) 
# including patients with lymphoma NOS, Non-Hodgkin lymphoma NOS and one patient with diffuse large B-cell 
lymphoma 
§ other malignancies that occurred after the diagnosis of chronic lymphocytic leukaemia 
Charlson comorbidity weighted index 
During follow-up, the majority of patients (n=1,425, 60.1%) in the study population had 
none of the comorbidities defined in the Charlson comorbidity weighted index (Table 4.1-1). 
Of those with comorbidities, 857 (90.5%) had a Charlson comorbidity weighted index 
ranging from one to three. Chronic obstructive pulmonary disease (n=189) was more 
common in men (n=136) than in women (n=53) (72% vs. 28%, p<0.001), as were 
congestive heart failure (n=95, 64 men, 31 women, 67% vs. 33%, p=0.064), and 
hypertension (n=406, 221 men, 185 women, 54% vs. 46%, p=0.098), whereas dementia 
(n=60, 28 men, 32 women) was more common in women (53% vs. 47%, p=0.068). 
Between 2000 and 2012, there was a significant trend of decreasing average Charlson 
comorbidity weighted index (-7.4%, 95% CI -9.1, -5.8%, p<0.001) per year. 
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Follow-up and survival 
Median follow-up after the diagnosis of CLL was 3.3 years (IQR 4.7 years, range: 0.02-
12.4 years). About a third of all CLL patients (n=802, 31.1%) died from any cause during 
follow-up. The overall Kaplan-Meier estimate of median survival was 8.6 years from the 
year of diagnosis (Figure 4.1-3). Survival significantly (p<0.001) differed by gender, age at 
diagnosis, and Charlson comorbidity weighted index (Figure 4.1-3): males had a shorter 
survival than females (adjusted hazard ratio [HR] 1.5, 95% CI 1.3, 1.7); survival decreased 
per year increase in age at diagnosis (adjusted HR 1.08, 95% CI 1.07, 1.09) and decreased 
with one unit increase in Charlson comorbidity weighted index (adjusted HR 2.3, 95% CI 
1.5, 3.6). A CLL diagnosis in the years 2001 to 2012 compared to a CLL diagnosis in 2000 
was borderline significantly associated (p=0.077) with improved survival (HR 0.98, 95% CI 
0.95, 1.0).  
Figure 4.1-3: Kaplan-Meier estimate of overall survival 
 
 
 
CCI, Charlson comorbidity weighted index  
Kaplan-Meier estimate of a) overall survival, b) overall survival stratified by gender, c) overall survival stratified by age 
group and d) overall survival stratified by Charlson comorbidity weighted index  
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Medical resource utilisation 
During a median follow-up of 3.3 (IQR 4.7) years after the diagnosis of CLL, patients had 
on average 74.6 GP visits, 3.2 referrals to specialists or specialised clinics, 0.5 
hospitalisations and 0.1 chemotherapies or radiotherapies, as presented in detail in table 
2. Prescriptions of immunosuppressants, chemotherapeutics, or antiemetics per patient 
per year were: 0.1 prescriptions for immunosuppressants, 0.6 prescriptions for 
chemotherapeutics and 1.1 prescriptions for antiemetics, respectively. Prescriptions 
included chemotherapeutic agents such as fludarabine (n=2), cyclophosphamide (n=3), 
prednisolone (n=709), and chlorambucil (n=35). No presctiption codes for monoclonal 
antibodies such as rituximab were recorded in our study population.  
Between 2000 to 2012, the average number of recorded referrals to a specialist or 
specialised clinic and the average number of recorded hospitalisations per year (corrected 
for duration of follow-up) significantly increased by 8.1% (95% CI 6.8, 9.3%) and 16.4% 
(95% CI 15.4, 17.3%), respectively. In the same time period, a small increase in the number 
of referrals and hospitalisations per patient per year (corrected for duration of follow-up) 
was observed (Table 4.1-2). 
In the first year following the CLL diagnosis, 0.8 referrals were recorded on average. The 
average number of recorded referrals was 0.5 in the second year following the CLL 
diagnosis, corresponding to a significant decrease of 35.3% (95% CI 28.8, 70.2%). On 
average, 0.13 hospitalisations were recorded in the first year following the CLL diagnosis 
and 0.09 hospitalisations in the second year following the CLL diagnosis. This corresponds 
to a significant decrease by 29.4% (95% CI 12.8, 45.9%).  
Table 4.1-2: Medical resource utilisation from 2000-2012 
Item Average 
number 
during mean 
follow-up of 
4.1 years 
SD range Average 
number per 
patient per 
year* 
SD range 
GP visits 
First visit after CLL diagnosis on 
average within (days) 
In the first year following the CLL 
diagnosis 
74.6 
16.5 
 
NA 
 
65.3 
39.3 
 
NA 
 
1-417 
1-1304 
 
NA 
 
22.2 
NA 
 
17.6 
 
17.1 
NA 
 
13.0 
 
1-302 
NA 
 
1-162 
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Item Average 
number 
during mean 
follow-up of 
4.1 years 
SD range Average 
number per 
patient per 
year* 
SD range 
Referrals  
First referral after CLL diagnosis on 
average within (years) 
In the first year following the CLL 
diagnosis 
3.2 
1.1 
 
NA  
 
4.4 
1.5 
 
NA 
 
0-65 
0-9.6 
 
NA 
 
1.0 
NA 
 
0.8 
 
2.4 
NA 
 
1.3 
 
0-41 
NA 
 
0-20 
 
Hospitalisations  
First hospitalisation after CLL 
diagnosis on average within (yrs)  
In the first year following the CLL 
diagnosis 
0.5 
2.5 
 
NA  
1.2 
2.4 
 
NA 
0-14 
0-11.1 
 
NA 
0.3 
NA 
 
0.1 
 
2.2 
NA 
 
0.5 
 
0-81 
NA 
 
0-7 
Chemotherapy and Radiotherapy 
First therapy after CLL diagnosis on 
average within (years) 
Blood transfusion 
First blood transfusion after CLL 
diagnosis on average within (yrs) 
0.1  
2.5 
 
 
0.1 
2.9  
0.6 
2.4 
 
 
1.7 
2.8 
0-9 
0-10.4 
 
 
0-72 
0-9.9 
0.05 
NA 
 
 
0.06 
NA 
0.3 
NA 
 
 
0.7 
NA 
0-12 
NA 
 
 
0-21 
NA 
Tests and investigations 
Bone marrow examination (n=4) 
Haemoglobin (n=2,146) 
Neutrophil count (n=2,034) 
Red blood cell count (n=1,953) 
White blood cell count (n=2,137) 
Platelets (n=2,131) 
 
1.3 
8.2 
7.5 
6.4 
8.2 
9.0 
 
0.5 
10.0 
8.8 
7.7 
10.0 
11.2 
 
1-2 
1-136 
1-112 
1-95 
1-138 
1-138 
 
- 
2.3 
2.1 
1.8 
2.3 
2.5 
 
- 
2.7 
2.6 
2.7 
2.8 
3.2 
 
- 
0.1-37 
0.1-37 
0.1-61 
0.1-39 
0.1-61 
Prescriptions  
Chemotherapeutics  
Immunsuppresives 
Antiemetics  
Antidepressants  
Antifungals 
Antibiotics 
Antivirals 
Growth factors 
 
1.9  
0.4 
3.6 
5.9 
0.7 
7.0 
0.6 
0.03 
 
14.3 
6.8 
16.3 
19.4 
2.9 
12.7 
3.0 
0.8 
 
0-595 
0-297 
0-362 
0-315 
0-55 
0-158 
0-63 
0-35 
 
0.6 
0.1 
1.1 
1.6 
0.2 
1.8 
0.1 
0.01 
 
2.9 
1.1 
4.3 
4.8 
1.2 
3.1 
0.8 
0.3 
 
0-69 
0-35 
0-101 
0-56 
0-20 
0-55 
0-16 
0-12 
Trend analyses 
Item Estimate 95% CI p-value 
Change in average number of referrals per year 16.4% 15.4%, 17.3% p<0.001 
Change in number of referrals per patient per year 0.05% 0.04%, 0.06% p<0.001 
Change in average number of referrals in the second year 
compared to the first year following the CLL diagnosis 
-35.3% -28.8%, -70.2% p<0.001 
Change in average number of hospitalisations per year 8.1% 6.8%, 9.3% p<0.001 
Change in number of hospitalisations per patient per year 0.05% 0.02%, 0.08% p=0.002 
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Item Estimate 95% CI p-value 
Change in average number of hospitalisations in the 
second year compared to the first year following the CLL 
diagnosis 
-29.4% -12.8%, -45.9%  p<0.001 
CI, confidence interval; CLL, chronic lymphocytic leukaemia; GP, general practitioner; NA, not applicable; SD, standard 
deviation; yrs, years 
Where n is not specified, the number was obtained including all patients 
* corrected for follow-up 
Discussion 
In this large epidemiological study based on  primary care data from the UK CPRD, we 
identified 2,576 eligible adult patients with a diagnosis of CLL between 2000 and 2012. 
The overall age-standardised incidence rate was 6.2/100,000 (95% CI 6.0, 6.5/100,000) 
person-years. We found that CLL incidence rates in the UK CPRD increased slightly 
between 2000 and 2005 and then stabilised between 2006 and 2010. Male and elderly 
patients were more often diagnosed with CLL. More than a third of the patients had 
comorbidities defined in the Charlson comorbidity weighted index. Overall median survival 
after the CLL diagnosis was about 9 years and significantly differed by age, gender and 
Charlson comorbidity weighted index. The average number of recorded referrals to a 
specialist or specialised clinic and hospitalisations per patient per year significantly 
increased between 2000 and 2012. Referrals and hospitalisations were less frequent in 
the second year following the CLL diagnosis compared to the first year following the CLL 
diagnosis.  
Our estimate of the crude incidence rate of CLL in the CPRD population (7.2/100,000, 95% 
CI 6.9, 7.4/100,000 person-years) was higher than the one reported in a Czech study (5.8 
and 6.2/100,000 people in 2006 and 2007, respectively) [167]. Compared to our age-
standardised incidence rate estimate of 6.2/100,000 person-years, lower cancer registry-
based age-standardised incidence rates of CLL (3.8/100,000 person-years over a 20-year  
time period) were reported for the Netherlands [168] and for the UK (3.6/100,000 people 
in 2009) [169]. Our estimate was higher, most likely because haematological malignancies 
are more frequently recorded in the CPRD compared to cancer registries [170] and we 
used the new European standard population, published in 2013 [164], to calculate age-
standardised incidence rates. We observed a trend of increasing CLL incidence rates with 
increasing year of study, although the difference did not reach statistical significance. 
Notably, between 2003 and 2009, annual incidence rates of all cancers in the UK also 
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increased [169]. An observed decline in the incidence rate between 2011 and 2012 as 
shown in figure 2 was likley explained by the fact that data were only availabe through 
June 2012.  
In our study, CLL occurred more often in males and elderly patients. More than a third of 
the CLL patients had comorbidities as defined by the Charlson comorbidity weighted index 
[165]. A similar pattern was seen in a Danish study of different types of cancer including 
leukaemia [171]. The average Charlson comorbidity weighted index in the CPRD 
population significantly decreased between 2000 and 2012. This is probably because high 
risk patients presenting with several comorbidities are being managed in the hospital and 
not in primary care. Although patients are currently diagnosed  at an earlier disease stage 
[63], the median age at CLL diagnosis is still above 70 years and a substantial proportion 
of the patients have one or more comorbidities [154] as defined in the Charlson comorbidity 
weighted index [165]. The Cumulative Illness Rating Scale (CIRS), which is often used to 
assess the health status in patients with CLL, could not be applied [172,173]. The severity 
of morbidities recorded in the CPRD was not provided for all morbidities. For example, the 
CPRD coding system does not provide a code that allows a straightforward differentiation 
between mild, moderate or severe disease in the case of mental or metabolic illnesses.  
During the time period from 2000 to 2012, average medical resource utilisation per year in 
terms of number of recorded referrals and hospitalisations increased significantly. As our 
trend analyses were controlled for duration of follow-up, the changes in medical resource 
utilisation may reflect real changes rather than a cohort effect. But the increase could also 
be due to changes in the way GPs recorded these referrals and hospitalisations. The 
OECD Health Data 2013 [174] found that the number of GP visits reported for the general 
UK population decreased over time. On the other hand, key statistics of the UK NHS 
reported an increase in hospital admissions and outpatient appointments for the general 
UK population [175]. Changing clinical practice patterns may partly explain the change in 
medical resource utilisation. The decreasing number of referrals and hospitalisations found 
in the CPRD population in the second year compared to the first year following the CLL 
diagnosis could reflect referral back into the community for GP follow-up of low risk patients 
(i.e. to monitor disease progression). An increase of referrals and hospitalisations in the 
CPRD population could reflect need for immediate treatment after initial CLL diagnosis.  
To our knowledge, this is the first study to describe population-based incidence rates and 
trends in medical resource utilisation in CLL patients using UK-based primary care data. 
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Previous literature suggests that most of the diagnoses coded in the CPRD are accurately 
recorded and agree with other databases and national statistics [176], and cancer 
registries [170]. The validity of the CLL diagnosis was further assessed by screening 
random records of 100 CLL patients for CLL-concomitant laboratory measures, diagnostic 
tests and symptoms. The CLL diagnosis was considered validated if the patient record 
included at least one screening criterion for CLL. Only patients with at least three years of 
recorded history in the CPRD prior to the CLL diagnosis were included in our analysis to 
increase the probability of including only incident rather than prevalent cases Therefore, 
we are confident that the estimated incidence rates are reliable and generalisable to the 
UK population.  
This study has several limitations that should be considered in interpreting our findings. 
Although about 70% of the CLL cases are diagnosed in asymptomatic patients [63] when 
they visit the GP for a routine blood count, some CLL cases may remain undetected 
because there is no visit to the GP for a routine blood count. Detection bias may limit the 
interpretation of our observed gender differences, as women may see the GP more often 
than men [177]. Total medical resource utilisation of CLL patients was incompletely 
assessed because details about secondary and tertiary care are not consistently recorded 
in the CPRD. Therefore, the recorded number of referrals and hospitalisations in the CPRD 
may be an underestimate. Details about type of chemotherapy regimen, for example, are 
often lacking as few chemotherapies are administered in the ambulatory setting.  
Medical records of GPs are a valuable source to estimate population-based CLL 
incidences and trends in incidences in the UK. Further research to assess details of 
medical resource utilisation in secondary and tertiary care, especially regarding 
chemotherapy use, is needed to better understand total medical resource utilisation and 
treatment patterns in CLL.  
Conclusion 
Consistent with previous literature, we found that CLL incidence rates in the UK increased 
over time. However, in the past five years, we observed a stabilisation of CLL incidence 
rates in the CPRD population, which has not been previously reported in the literature. 
Further research to determine CLL-specific mortality and resource utilisation in non-
primary care is needed as cancer patients are often treated in hospitals.  
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Abstract  
Background: Febrile neutropenia (FN) is common in breast cancer patients undergoing 
chemotherapy. Risk factors for FN have been reported, but risk models including genetic 
variability have yet to be described. This study aimed to evaluate the predictive value of 
patient-related, chemotherapy-related and genetic risk factors.  
Methods: Data from consecutive breast cancer patients receiving chemotherapy with 4-6 
cycles of fluorouracil, epirubicin and cyclophosphamide (FEC) or 3 cycles of FEC and 
docetaxel were retrospectively recorded. Multivariable logistic regression was carried out 
to assess risk of FN during FEC chemotherapy cycles.  
Results: Overall, 166 (16.7%) out of 994 patients developed FN. Significant risk factors 
for FN in any cycle and the first cycle were lower platelet count (OR=0.78 [0.65;0.93]) and 
haemoglobin (OR=0.81 [0.67;0.98]) and homozygous carriers of the rs4148350 variant T-
allele (6.7 [1.04;43.17]) in MRP1. Other significant factors for FN in any cycle were higher 
alanine aminotransferase (OR=1.02 [1.01;1.03]), carriers of the rs246221 variant C-allele 
(OR=2.0 [1.03;3.86]) in MRP1 and the rs351855 variant C-allele (OR=2.48 [1.13;5.44]) in 
FGFR4. Lower height (OR=0.62 [0.41;0.92]) increased risk for FN in cycle 1.  
Conclusions: Both established clinical risk factors and genetic factors predicted FN in 
breast cancer patients. Prediction was improved by adding genetic information but overall 
remained limited. Internal validity was satisfactory. Further independent validation is 
required to confirm these findings. 
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Background  
Chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) are serious and 
frequent complications in patients with breast cancer receiving adjuvant chemotherapy, 
and they result in hospitalisations [101,178,179] and chemotherapy dose reductions or 
delays that impact on treatment outcome and short-term mortality [102]. Adjuvant 
fluorouracil, epirubicin, and cyclophosphamide (FEC) chemotherapy has an FN risk of 
between 9% and 14% (low-intermediate risk) [98].  
Antibacterial or antifungal prophylaxis has recently been recommended for neutropenic 
patients expected to have a prolonged low neutrophil count or with other risk factors that 
favour complications [144]. Prophylaxis with granulocyte colony-stimulating factor (GCSF) 
in patients at high risk of FN (>20%) is recommended in international guidelines 
[98,141,142]. For chemotherapy regimens with an intermediate FN risk (10-20%), the 
European Organisation for Research and Treatment of Cancer (EORTC) G-CSF guideline 
recommends that patient risk factors should also be considered to determine individual risk 
of FN [98] and the likely benefit of prophylactic GCSF. Therefore, it is important to identify 
patients at high risk of FN before the initiation of chemotherapy to provide them with 
appropriate prophylactic measures. 
Risk models for the occurrence of CIN [106] and FN [104] in patients with breast cancer 
have been published. The risk factors identified included: older age, lower weight, higher 
planned dose of chemotherapy, higher number of planned chemotherapy cycles, vascular 
comorbidity, lower baseline white blood cell count (WBC), lower platelet and neutrophil 
count and higher baseline bilirubin. Prior chemotherapy, abnormal liver or renal function, 
low WBC, higher chemotherapy intensity and planned delivery were identified as risk 
factors for neutropenic complications in a prospective US study of patients with different 
types of cancer [130]. Poor performance status and low lymphocyte and neutrophil counts 
were risk factors in a European study of solid tumour patients [131], as were tumour stage 
and number of comorbidities in elderly patients with solid tumours [113].  
These risk models of CIN or FN that included patient- or chemotherapy-related factors 
were reported to be predictive. However, more refined models are necessary to achieve 
satisfactory performance in independent patient populations that include existing and 
emerging types of data, including stable genetic factors that are easily measurable, 
objective, and potentially independent from the inherent viabilities of clinical decision-
making. Several studies have assessed the impact of genetic factors on haematological 
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toxicity, but these studies were small in size or limited to only a few candidate genetic 
factors [122,124,125]. 
The objective of this study was to develop risk models for the occurrence of FN in breast 
cancer patients receiving FEC chemotherapy in any cycle and the first cycle based on a 
large set of patient-related, chemotherapy-related, and genetic characteristics.  
Methods 
Study population 
We retrospectively studied early (i.e., no distant metastases; Stage I-IIIC) breast cancer 
patients treated between 2000 and 2010 at the Leuven Multidisciplinary Breast Cancer 
Center of the University Hospitals Leuven, Belgium. Consecutive patients were included if 
they received either three cycles of neoadjuvant or adjuvant combination chemotherapy 
consisting of FEC followed by three cycles of docetaxel or four to six cycles of FEC. Patient-
related factors (genetics and tumour characteristics) and chemotherapy-related factors 
were retrospectively recorded in a clinical database. Haematological toxicities included 
were: FN (defined as an absolute neutrophil count (ANC) < 0.5 x 109/L and a body 
temperature ≥ 38°C according to the Infectious Diseases Society of America), prolonged 
grade 4 neutropenia (≥ 5 days), deep neutropenia (< 100/µl), grade 3/4 thrombocytopenia, 
and grade 3/4 anaemia during FEC chemotherapy cycles. Haematological toxicities that 
occurred during chemotherapy cycles with docetaxel were not included in the model. 
Grade 3/4 non-haematological toxicities were also recorded (toxicity grade based on the 
Common Terminology Criteria for Adverse Events 3.0 [180]). During most of the study 
period, only primary prevention with GCSF was reimbursed and, therefore, only used in 
selected patients aged 65 or over. Similarly, secondary use of GCSF was only reimbursed 
and used if patients had FN in the previous cycle or if deep neutropenia occurred for at 
least five days (although the latter was not systematically measured during the study 
period).  
The study design and full analysis of single nucleotide polymorphisms (SNPs) have 
previously been described in detail [126]; however, in the previous analysis the association 
of SNPs with FN was only adjusted for age, growth factor use, BMI, and planned cycles of 
chemotherapy. Only those SNPs that have been reported to be associated with 
haematological toxicity or to play a role in the metabolism of FEC chemotherapy were 
included in the current study. Logistic regression was performed to describe the 
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association of SNPs with haematological toxicity, adjusted for known predictors of FN risk 
such as age, growth factor use, and planned number of cycles of chemotherapy. The ethics 
committee of the University Hospitals Leuven approved the study and all patients included 
in the study had given written informed consent for collection of genetic samples and for 
further analyses using this material and associated data. 
Endpoints and predictor variables 
The primary endpoint of the study was FN in any cycle, and FN occurring in the first cycle 
(cycle 1) was the secondary endpoint. The following variables were considered as 
predictors of FN: planned doses of fluorouracil, epirubicin and cyclophosphamide (FC, 600 
mg/m2 until August 2004 and 500 mg/m2 after this date; epirubicin 100 mg/m2), age at 
diagnosis, height, weight, body mass index (BMI), body surface area (BSA), chemotherapy 
setting (i.e. adjuvant or neoadjuvant), use of GCSF (information only available on primary 
or secondary use), planned cycles of FEC chemotherapy, selected SNPs [126], baseline 
WBC, ANC and platelet count, and other baseline laboratory parameters such as 
haemoglobin, bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST) 
and creatinine. Although timing and reasoning of GCSF use were incomplete, its potential 
impact on the variables included in the final model was assessed for exploratory analysis. 
Statistical analysis 
All analyses were performed using Stata/SE version 12.1 (StataCorp LP, College Station, 
TX, USA). All statistical tests were carried out two-sided at a 5% significance level and 
95% confidence intervals (CIs) were obtained.  
Descriptive and univariable analysis 
Binary and categorical data were summarised using frequencies and percentages. 
Continuous data were reported using means and standard deviations. In the univariable 
analysis of SNPs, the impact of multiple testing was assessed by separately calculating 
the false discovery rate (FDR) for each endpoint [181]. Associations between the endpoints 
and binary or categorical variables were assessed using the chi-squared test or Fisher’s 
exact test, as appropriate. Continuous variables and their associations with the endpoints 
were assessed using univariable logistic regression analysis. Variables were further 
assessed in multivariable logistic regression analysis if a trend was seen in the univariable 
analysis (p ≤ 0.25), as recommended [182]. Linear correlation between potential predictors 
were assessed by calculating Pearson’s correlation coefficient and monotonic correlations 
were assessed using Spearman’s rank correlation coefficient. Variables were regarded as 
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being dependent if the correlation coefficient was ≥ 0.7 or the correlation p-value was ≤ 
0.05. 
Multivariable analysis 
Multivariable logistic regression analysis was used to assess the joint explanatory value of 
the candidate variables identified in univariable analysis; variables were included in the 
final multivariable models if their corresponding p-value was ≤ 0.05. Where simultaneous 
inclusion of dependent variables led to estimation problems (collinearity issues), the 
variable that explained more of the variability present in the endpoint was finally used. As 
patient-related and chemotherapy-related factors were already established as risk factors 
in several previous risk models, these variables were entered into the model first, ordered 
according to the p-value obtained in univariable analysis. SNPs were subsequently added. 
Interactions between variables were assessed. Model fit was assessed with the Hosmer-
Lemeshow [183] goodness-of-fit test. Test characteristics such as specificity (proportion of 
negatives correctly identified as not having an event), sensitivity (proportion of positives 
correctly identified as having an event), positive predictive value (PPV, proportion of 
patients identified to have an event who had an event) and negative predictive value (NPV, 
proportion of patients identified not to have an event who did not have an event) were 
obtained. The predictive ability of the final models was assessed by calculating the area 
under the receiver operating characteristic (ROC; sensitivity over 1-specificity) curve.  
To test the internal validity of the final models, nonparametric bootstrapping was performed 
[184]. Bootstrap estimates of the 95% CIs of the multivariable models were obtained by 
resampling the data 200 times. The obtained 95% CI estimates of the bootstrap resampling 
were compared to the 95% CIs calculated by the multivariable logistic regression model.  
Results  
Characteristics of the study group 
Of 1,012 patients that received FEC chemotherapy between 2000 and 2010, 18 patients 
were excluded due to receiving chemotherapy prior to FEC, which may have impacted on 
FN risk. The majority of 994 eligible patients received adjuvant chemotherapy (n = 874, 
88.0%); the remainder received neoadjuvant chemotherapy. Most patients received three 
cycles of combination chemotherapy with FEC followed by three cycles of docetaxel (n = 
507, 51.0%) or six cycles of FEC (n = 405, 40.7%) (Table 4.2-1). The most common type 
of breast cancer was invasive ductal carcinoma (n = 823, 82.8%) and patients mostly had 
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grade 2 (n = 334, 34.1%) or grade 3 (n = 606, 61.9%) tumours. FN occurred in any cycle 
in 166 (16.7%) patients, of which 107 (10.8%) had FN in the first cycle of FEC 
chemotherapy. The most common haematological toxicity was prolonged grade 4 
neutropenia (n = 345, 34.7%). Other haematological toxicities such as grade 3/4 
thrombocytopenia and severe bleeding, and grade 3/4 non-haematological toxicities such 
as diarrhoea, mucositis, and neuropathy were rare (n < 10, <1%). Primary prophylactic 
GCSF (before a CIN or FN event occurred) was given to 15 (1.5%) patients and the 
majority received no GCSF (n = 654, 65.8%). Additional toxicities and other relevant 
characteristics such as planned number of chemotherapy cycles, tumour stage, and 
subtype are presented in Table 4.2-1. The list of SNPs included in the analyses is shown 
in Table 4.2-2. 
Table 4.2-1: Characteristics of the study population, the tumours, and the administered 
chemotherapy including toxicities 
Patient characteristics  Mean ± standard deviation 
or frequency (%) 
Age at diagnosis (years) (n = 994) 50.4 ± 9.6 
Body mass index (kg/m2) (n = 981) 24.9 ± 4.1 
Body surface area (m2) (n = 993) 1.7 ± 0.1 
Tumour characteristics  
Tumor Stadium  
Primary tumour 
Relapsed tumour 
994 (100) 
966 (97.2) 
28 (2.8) 
Tumour gradea  
1 
2 
3 
979 (98.5) 
39 (4.0) 
334 (34.1) 
606 (61.9) 
Tumour type  
Invasive ductal carcinoma 
Invasive lobular carcinoma 
mixed 
others 
994 (100) 
823 (82.8) 
103 (10.4) 
27 (2.7) 
41 (4.1) 
Tumour stageb  
I 
IIA 
IIB 
IIIA 
IIIB 
IIIC 
978 (98.4) 
113 (11.5) 
306 (31.3) 
245 (25.1) 
193 (19.7) 
44 (4.5) 
77 (7.9) 
Receptor status 
estrogen receptor positive 
progesterone receptor positive 
 
683 (68.8) 
577 (58.1) 
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Tumour characteristics 
Receptor status 
HER2 positive 
 
 
205 (20.7) 
Subtypec  
luminalA 
luminalB HER2- 
luminalB HER2+ 
HER2-like 
triple negative 
981 (98.7) 
325 (33.1) 
234 (23.9)  
121 (12.3) 
84 (8.6) 
217 (22.1) 
Nottingham Prognostic Index (NPI)d (n = 757) 5.0 ± 0.9 
Chemotherapy characteristics  
Chemotherapy setting 
adjuvant 
neoadjuvant 
994 (100) 
874 (87.9) 
120 (12.1) 
Planned cycles of FEC chemotherapy  
3 cycles FEC 
Chemotherapy characteristics 
994 (100) 
559 (56.2) 
 
Planned cycles of FEC chemotherapy 
4 or 5 cycles FEC 
6 cycles FEC 
 
2 (0.2) 
433 (43.6) 
Relative dose intensity (RDI) (n = 994) 0.96 ± 0.1 
Growth factor use 
primary 
secondary 
none 
994 (100) 
15 (1.5) 
325 (32.7) 
654 (65.8) 
Baseline laboratory parameters  
White blood cell count (109/L) (n = 985) 7.2 ± 2.0 
Absolute neutrophil count (109/L) (n = 937) 4.4 ± 1.6 
Haemoglobin (g/dl) (n = 989) 13.3 ± 1.0 
Platelets (109/L) (n = 985) 275.4 ± 65.1 
Total bilirubin (mg/dl) (n = 915) 0.4 ± 0.2 
Creatinine (mg/dl) (n = 957) 0.8 ± 0.1 
Alanine aminotransferase (U/L) (n = 955) 23.3 ± 15.3 
Aspartate aminotransferase (U/L) (n = 955) 21.9 ± 11.1 
FEC chemotherapy toxicities  
Febrile neutropenia  
- Febrile neutropenia in first cycle 
166 (16.7) 
107 (10.7) 
Prolonged (≥ 5 days) grade 4 neutropenia 345 (34.7) 
Deep neutropenia (< 100/µl) 93 (9.4) 
Other grade 3-4 toxicities 46 (4.6) 
FEC, fluorouracil, epirubicin and cyclophosphamide; HER2, human epidermal growth factor receptor 2 
a according to the Ellis and Elston grading system [185] 
b according to the TNM classification [186] 
c according to Brouckaert et al. [187] 
d according to Lee et al. [188] 
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Table 4.2-2: List of included single nucleotide polymorphisms (SNPs), and their 
frequencies (percentages) 
 Genotype 
Gene n GG 
n (%) 
GA 
n (%) 
AA 
n (%) 
CC 
n (%) 
CA 
n (%) 
ABCC2/MRP2rs8187710  954 842 (88.3) 110 (11.5) 2 (0.2)   
ABCG2/BRCPrs2231137  955 888 (93.0) 67 (7.0)    
CYP2B6rs2279343 910 57 (6.2) 382 (42.0) 471 (51.8)   
CYP2C8rs72558196 960   960 (100)   
CYP2C9rs1057910 954   853 (89.4) 3 (0.3) 98 (10.3) 
CYP2C19rs4244285 946 652 (68.9) 266 (28.1) 28 (3.0)   
CYP2C19rs4986893  960 960 (100)     
CYP3A4rs2740574 955 2 (0.2) 57 (6) 896 (93.8)   
CYP3A4rs55785340 957   957 (100)   
CYP3A5rs776746 959 834 (87.0) 118 (12.3) 7 (0.7)   
DPYDrs1801159  960 47 (4.9) 267 (27.8) 646 (67.3)   
DPYDrs3918290 949 945 (99.6) 4 (0.4)    
DPYDrs1801160 957 853 (89.1) 96 (10.0) 8 (0.9)   
GSTA1rs3957357 938 329 (35.1) 441 (47.0) 168 (17.9)   
GSTP1rs1695  959 118 (12.3) 452 (47.1) 389 (40.6)   
MRP1rs1883112 956 295 (30.9) 485 (50.7) 176 (18.4)   
MRP1rs7853758 952 701 (73.6) 231 (24.3) 20 (2.1)   
MTHFRrs1801131 951   446 (46.9) 92 (9.7) 413 (43.4) 
UGT2B7rs12233719 949 949 (100)     
UGT2B7rs7662029 955 210 (22.0) 473 (49.5) 272 (28.5)   
XPD/ERCC2rs1799793 954 412 (43.2) 429 (45.0) 113 (11.8)   
XRCC1rs25489 954 875 (91.7) 77 (8.1) 2 (0.2)   
XRCC3rs861534 949 357 (37.6) 441 (46.5) 151 (15.9)   
Gene  
n 
TT 
n (%) 
CC 
n (%) 
CT 
n (%) 
AA 
n (%)  
TA 
n (%) 
ABCC2/MRP2rs17222723 951 843 (88.6)   2 (0.2) 106 (11.2) 
ABCC2/MRP2rs2804402 935 297 (31.8) 185 (19.8) 453 (48.4)   
CYP2B6rs8192709 927  846 (91.3) 87 (8.7)   
CYP2C8rs10509681 960 740 (77.1) 12 (1.2) 208 (21.7)   
CYP2C9rs1799853 957 15 (1.6) 712 (74.4) 230 (24)   
CYP3A4rs4986910 959 938 (97.8)  21 (2.2)   
DPYDrs1801265  960 635 (66.1) 46 (4.8) 279 (29.1)   
Gene n TT 
n (%) 
CC 
n (%) 
CT 
n (%) 
AA 
n (%)  
TA 
n (%) 
FGFR4rs351855 954 88 (9.2) 461 (48.3) 405 (42.5)   
GSTP1rs1138272 952 6 (0.6) 778 (81.7) 168 (17.7)   
MDRI/ABCB1rs1045642 914 265 (29.0) 208 (22.8) 441 (48.2)   
MRP1rs13058338 949 482 (50.8)   67 (7.1) 400 (42.1) 
MRP1rs246221 956 462 (48.3) 71 (7.4) 423 (44.3)   
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Gene n TT 
n (%) 
CC 
n (%) 
CT 
n (%) 
AA 
n (%)  
TA 
n (%) 
MRP1rs3743527 930 13 (1.4) 562 (60.4) 355 (38.2)   
MRP1rs4673  954 115 (12.0) 406 (42.6) 433 (45.4)   
MTHFRrs1801133 959 121 (12.6) 401 (41.8) 437 (45.6)   
NQO1rs1800566 958 35 (3.6) 605 (63.2) 318 (33.2)   
UGT2B7rs7439366 955 272 (28.5) 210 (22.0) 473 (49.5)   
UGT2B7rs7668282 954 940 (98.5) 1 (0.1) 13 (1.4)   
Gene n GG 
n (%) 
GT 
n (%) 
TT 
n (%) 
CC 
n (%)  
CG 
n (%) 
ALDH3A1rs2228100 934 67 (7.2)   554 (59.3) 313 (33.5) 
CYP2B6rs3745274 954 535 (56.1) 365 (38.2) 54 (5.7)   
GPX4rs757229 940 263 (28.0)   212 (22.5) 465 (49.5) 
MRP1rs4148350 957 847 (88.5) 105 (11.0) 5 (0.5)   
MRP1rs45511401 960 847 (88.2) 109 (11.4) 4 (0.4)   
UGT2B7rs3924194 954 19 (2.0%)   712 (74.6) 223 (23.4) 
XPD/ERCC2rs13181 951 116 (12.2) 449 (47.2) 386 (40.6)   
Gene n GG 
n (%) 
GT 
n (%) 
TT 
n (%) 
GA 
n (%)  
TA 
n (%) 
MDRI/ABCB1rs2032582 948 283 (29.9) 445 (46.9) 185 (19.5) 23 (2.4) 12 (1.3) 
TYMSrs11280056 918 AAGTTA  
442 (48.2) 
AAGTTA.DEL      
394 (42.9) 
DEL  
82 (8.9) 
 
Univariable analysis 
All candidate predictors (p ≤ 0.25) for FN in any cycle and in cycle 1 are shown in Table 
4.2-3. Patient-related factors (genetics, laboratory parameters, etc.) and chemotherapy-
related factors fulfilled the inclusion criteria for the multivariable analysis. The number of 
planned FEC cycles, WBC, ANC, platelet count, and haemoglobin were significantly 
associated with FN in any cycle and cycle 1 (p ≤ 0.5).  SNPs significantly associated with 
FN in any cycle and cycle 1 were the rs4148350, rs45511401, and rs246221 variants in 
MRP1 (multidrug resistance-associated protein 1). The FDR for associated SNPs for any 
cycle FN was 0.47 and 0.33 for cycle 1 FN. There were no correlations between SNPs 
included in the final model and patient-related or chemotherapy-related factors. 
Risk factors of febrile neutropenia in any cycle 
Multivariable regression identified the following factors to be significantly associated with 
a higher occurrence of FN: lower platelet count and lower haemoglobin at baseline, higher 
ALT, and the following SNPs: rs4148350 and rs246221 in MRP1 and rs351855 in FGFR4 
(fibroblast growth factor receptor 4) (Table 4.2-4). Homozygous carriers of the rs4148350  
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T-allele had a higher risk of FN than carriers of the homozygous or heterozygous G-allele 
(FN risk of 80% versus 15% or 25%). For rs246221, homozygous carriers of the T-allele 
variant had a lower risk of FN than carriers with at least one C-allele (FN risk of 13% versus 
20% or 24%). Patients with the TT genotype of rs351855 were protected against FN 
compared to patients carrying at least one C-allele (FN risk of 10% versus 19% or 16%).  
Table 4.2-3: Candidate predictors from univariable analysis 
FN in any cycle FN in cycle 1 
Variable  OR (95% CI) p-
value 
OR (95% CI) p-
value 
Platelets (109/L, per 50 
units change) 
0.80 (0.69; 0.92) 0.002 0.78 (0.66; 0.93) 0.005 
ANC (109/L) 0.87 (0.77; 0.98) 0.023 0.86 (0.74; 1.00) 0.046 
ALT (U/L) 1.01 (1.00; 1.02) 0.024 - - 
WBC (109/L) 0.90 (0.83; 0.99) 0.032 0.88 (0.79; 0.99) 0.028 
Height (cm) - - 1.03 (1.00; 1.07) 0.043 
Haemoglobin (g/dl) 0.87 (0.73; 1.02) 0.094 0.80 (0.66; 0.98) 0.030 
Planned cycles FEC (6 vs. 
3 cycles) 
1.09 (0.98; 1.22) 0.129 - - 
ASTa (U/l) 1.00 (0.99; 1.02) 0.210 - - 
BSA (m2) - - 2.44 (0.59; 10.03) 0.217 
Creatinin (mg/dl) 2.04 (0.66; 6.33) 0.219 - - 
Planned dose of 
epirubicin (100mg/m2) 
- - 1.01 (0.99; 1.02) 0.217 
Single nucleotide 
polymorphisms 
OR (95% CI) p-
value 
OR (95% CI) p-
value 
MRP1rs4148350  
-GT vs. GG 
-TT vs. GG 
 
1.82 (1.12; 2.94) 
22.06 (2.45; 198.96) 
0.000 
0.015 
0.006 
 
2.09 (1.21; 3.61) 
6.30 (1.04; 38.28) 
0.004 
0.008 
0.045 
MRP1rs45511401b  
-GT vs. GG 
-TT vs. GG 
 
1.80 (1.12; 2.89) 
16.40 (1.69; 158.84) 
0.000 
0.015 
0.016 
 
1.82 (1.05; 3.17) 
9.20 (1.28; 66.20) 
0.004 
0.034 
0.027 
MRP1rs246221  
-TT vs. CC 
-TC vs. CC 
 
0.47 (0.25; 0.86) 
0.80 (0.44; 1.45) 
0.004 
0.014 
0.459 
 
0.49 (0.24; 1.00) 
0.80 (0.40; 1.61) 
0.039 
0.053 
0.530 
FGFR4rs351855  
-CT vs. CC 
-TT vs. CC 
 
1.25 (0.88; 1.77) 
0.60 (0.29; 1.24) 
0.098 
0.216 
0.166 
- - 
CYP3A4rs4986910  
-TC vs. TT 
 
0.24 (0.03; 1.84) 
0.171 - - 
XRCC3rs861534  
-GG vs. AA 
-GA vs. AA 
 
1.25 (0.76; 2.07) 
0.86 (0.52; 1.42) 
0.130 
0.381 
0.544 
 
1.73 (0.91; 3.29) 
1.03 (0.53; 1.99) 
0.044 
0.095 
0.930 
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Single nucleotide 
polymorphism 
OR (95% CI) p-
value 
OR (95% CI) p-
value 
TYMSrs11280056  
AAGTTA.DEL vs. AAGTTA 
DEL vs. AAGTTA 
 
0.88 (0.60; 1.27) 
 
1.60 (0.91; 2.82) 
0.114 
0.486 
 
0.100 
- - 
GSTP1rs1695 
-AG vs. AA 
-GG vs. AA 
 
0.75 (0.53; 1.08) 
0.70 (0.40; 1.25) 
0.228 
0.124 
0.231 
- - 
GSTA1rs3957357  
-GG vs. AA 
-GA vs. AA 
- -  
0.95 (0.49; 1.83) 
1.45 (0.80; 2.65) 
0.163 
0.875 
0.223 
ALDH3A1rs2228100  
-GG vs. CC 
-GC vs. CC 
- -  
1.86 (0.92; 3.76) 
1.27 (0.81; 1.98) 
0.188 
0.086 
0.297 
MRP1rs1883112  
-AG vs. AA 
-GG vs. AA 
- -  
0.87 (0.52; 1.46) 
0.59 (0.32; 1.08) 
0.187 
0.594 
0.087 
UGT2B7rs7439366  
-TT vs. CC 
-TC vs. CC 
- -  
1.08 (0.57; 2.04) 
1.52 (0.87; 2.65) 
0.204 
0.813 
0.139 
UGT2B7rs7662029  
-GG vs. AA 
-GA vs. AA 
- -  
0.93 (0.49; 1.75) 
1.41 (0.86; 2.31) 
0.204 
0.813 
0.174 
ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, aspartate aminotransferase; BMI, body mass 
index; BSA, body surface area;  CI, confidence interval; FEC, fluorouracil, epirubicin and cyclophosphamide; FN, febrile 
neutropenia; WBC, white blood cell count  
Odds ratios and 95% confidence intervals are reported per 1 unit change if not otherwise indicated 
a highly correlated with alanine aminotransferase (Pearson’s correlation coefficient 0.76) and not included in multivariable 
analysis 
b highly correlated with MRP1rs4148350 (Spearman correlation coefficient 0.81) and not included in multivariable 
analysis 
 
The area under the ROC curve was 0.661 (CI 0.629-0.691), as shown in Figure 4.2-1: a 
value of 1 would denote perfect discrimination and 0.5 discrimination no better than 
chance. Overall, 864 of 910 patients (84.0%) were correctly classified by the logistic 
regression model at a predicted probability cut-off of 0.5; six out of 150 having FN and 758 
out of 760 not having FN. Sensitivity was very low (4.0%) compared to specificity (99.7%). 
NPV and PPV were similar; the proportion of patients correctly identified not to have FN 
was 84.0% and the proportion of patients correctly identified to have FN was 75.0%. When 
the optimal cut-off of the model was used (i.e., predicted probability of 0.1609, where 
sensitivity and specificity were almost identical at 61.3%), the model correctly classified 
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61.2% of the patients and PPV and NPV were 23.8% and 88.9%, respectively.  
Figure 4.2-1: Receiver operating characteristic curves 
 
Receiver operating curve (ROC) for a) FN in any cycle and b) FN in cycle 1 
Bisecting line indicates a predictive ability that is no better than chance (ROC = 0.5) 
Internal validity of the FN in any cycle model was satisfactory; the 95% CIs of the bootstrap 
resampling were similar to the 95% CIs calculated by the multivariable logistic regression 
model. 
Risk factors of febrile neutropenia in cycle 1 
Lower platelet count, haemoglobin at baseline and lower patient height were significantly 
associated with a higher risk of FN in cycle 1 (Table 4.2-4). The SNP found to be 
significantly associated with FN in cycle 1 was rs4148350 in MRP1. For rs4148350, 
homozygous carriers of the T-allele had a higher risk of FN in cycle 1 than carriers of the 
homozygous or heterozygous G-allele (FN risk of 40% versus 10% or 18%). We found a 
statistically significant interaction between haemoglobin and height that increased the 
protective effect of higher haemoglobin and increased height but did not affect the other 
main effects of the model. 
The area under the ROC curve was 0.664 (CI 0.633-0.694) as presented in Figure 4.2-1. 
At a probability cut-off of 0.5, one out of 98 patients was correctly classified having FN in 
cycle 1 and all 839 patients without FN in cycle 1 were correctly classified not having FN 
(overall, 89.7% correct classifications). Sensitivity was very low (1.0%); specificity was 
100%, PPV was 100%, and NPV was 89.6%. At the optimal probability cut-off for the model 
(0.1041), 61.5% of the patients were correctly classified, sensitivity and specificity were 
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61%, PPV was 15.7%, and NPV was 93.1%. The 95% CIs of the bootstrap resampling 
were similar to the 95% CIs calculated by the multivariable logistic regression model, which 
supports the internal validity of the FN in the first cycle model. 
Table 4.2-4: Logistic regression models for febrile neutropenia occurrence in any cycle 
and the first cycle of chemotherapy 
Determinant FN in any cycle (n = 910) FN in cycle 1 (n = 937) 
Odds ratio (95% CI) p-
value 
Odds ratio (95% CI) p-
value 
Platelets (109/L, per 
50 units change) 
0.780 (0.671; 0.906) 0.001 0.777 (0.649; 0.929) 0.006 
HB (g/dl, per 1 unit 
change) 
0.812 (0.673; 0.978) 0.029 0.001 (<0.001; 0.194) 0.009 
Height (cm, per 1 
unit change) 
- - 0.617 (0.414; 0.919) 0.018 
Interaction (height 
and HB)a 
- - 1.040 (1.008; 1.072) 0.012 
ALT (U/L, per 1 unit 
change) 
1.016 (1.005; 1.027) 0.003 - - 
MRP1rs4148350  
- GTb vs. GG 
- TTc vs. GG 
 
1.494 (0.890; 2.507) 
17.13 (1.72; 170.90) 
0.019 
0.129 
0.016 
 
2.149 (1.226; 3.768) 
6.696 (1.039; 43.167) 
0.006 
0.008 
0.046 
MRP1rs246221  
- TTd vs. CC 
- TC vs. CC 
 
0.501 (0.259; 0.969) 
0.805 (0.423; 1.533) 
0.023 
0.040 
0.510 
- - 
FGFR4rs351855  
- CT vs. CC 
- TTe vs. CC 
 
1.253 (0.862; 1.821) 
0.505 (0.230; 1.113) 
0.062 
0.238 
0.090 
- - 
ALT, alanine aminotransferase; CI, Confidence interval; FN, febrile neutropenia; HB, haemoglobin 
a did not affect the odds ratio of the other main effects of the regression model 
b 105/957 (11.0%) patients are carriers of the GT genotype and 19 (18.1%) out of those 105 patients had febrile 
neutropenia in cycle 1 of chemotherapy 
c 5/957 (0.5%) patients are homozygous carriers of the T-allele and 4 (80%) out of those 5 patients had febrile 
neutropenia in any cycle of chemotherapy and 2 (40%) had febrile neutropenia in cycle 1 
d 462/956 (48.3%) patients are homozygous carriers of the T-allele and 59 (12.8%) out of those 462 patients had 
febrile neutropenia in any cycle of chemotherapy 
e 88/954 (9.2%) patients are homozygous carriers ot the T-allele and 9 (10.2%) out of those 88 patients had febrile 
neutropenia in any cycle of chemotherapy 
Discussion  
In this population of early breast cancer patients seen in routine clinical practice at a tertiary 
referral centre, we identified a set of genetic factors, in addition to patient-related and 
chemotherapy-related factors, that predict occurrence of FN in any cycle or the first cycle 
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of chemotherapy. Significant predictors of a higher risk of FN in any cycle and in cycle one  
were: lower baseline platelet count, lower baseline haemoglobin, and carriers of the 
rs4148350 T-allele variant in MRP1, especially homozygous T-allele carriers. Patients with 
lower ALT and homozygous carriers of the rs246221 variant T-allele in MRP1 and 
rs351855 variant T-allele in FGFR4 had a lower risk of FN occurrence. Although the 
predictive ability of the models was improved by including genetic factors, the overall 
predictive ability remained poor. Genetic effects were stable and FN occurrence was very 
high in patients with specific SNP allele variants.  
The observed effects of lower baseline platelet count and haemoglobin are consistent with 
previous reports. Baseline platelet count has been shown to differ between cancer patients 
with mild and severe haematological toxicity [125], and low haemoglobin has been 
mentioned as possible risk factor for FN [189] and survival [190]. In the model of FN 
occurrence in any cycle, higher baseline ALT was significantly associated with FN but not 
baseline bilirubin [106,191]. Both measures are indicators of liver function and since the 
liver detoxifies drugs like epirubicin [192], impaired liver function may be an important risk 
factor for FN occurrence in patients receiving chemotherapy with epirubicin. A predictive 
role for WBC or ANC in CIN and FN occurrence in cancer patients receiving chemotherapy 
has been described in other studies [104,106,130,131], but could not be confirmed in our 
models. Most SNPs previously associated with FN occurrence [126] and reported to be 
involved in anthracycline-induced cardiotoxicity [193-195] were confirmed in the 
multivariable analysis. The SNP rs45511401 was not included in the multivariable 
regression model as it was highly correlated with rs4148350, and the latter variant 
explained the model variability slightly better. There were no correlations between SNPs 
included in the final model and patient- or chemotherapy-related factors. 
International guidelines [98,141,142] and the literature [106,131] report age, planned dose 
intensity, and planned number of chemotherapy cycles to be important risk factors for CIN 
and FN during chemotherapy. These risk factors could not be confirmed in our models. 
Patient-specific approaches to clinical management were not recorded in detail in this 
study and might therefore have masked the effect of age on FN occurrence. In addition, 
the exact cycle of FN occurrence was not available after the first cycle. Factors previously 
reported to protect against CIN and FN in any cycle of chemotherapy, such as dose 
reductions, dose delays, or growth factor use before an event occurred, could not be 
investigated since the details, reasons, and timing information were not available and only 
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15 out of 994 patients received primary prophylaxis with GCSF, mainly due to 
reimbursement criteria.  
The apparent predictive ability, i.e., the predictive ability assessed in the ‘training’ dataset 
used to develop the models, was lower than in previously published models of CIN or FN 
occurrence in other cancers [105,106,130]. In these models, sensitivity and specificity at 
the optimal predicted probability cut-off was about 70% or higher, but in this study it 
remained below 70%. As commonly seen in models of FN occurrence, the NPV (≥ 90%) 
was much higher than the PPV because FN incidence is often around 20%; this implies an 
NPV of around 80% for simply assuming that FN does not occur in any patient. The areas 
under the ROC curves were relatively low but significantly higher than 0.5, the value 
indicating no predictive ability. In other words, the models allowed partial discrimination of 
patients at low or high risk of FN. Including genetic risk factors improved the models but 
absolute predictive ability remained rather low. The effects of the SNPs were stable and 
FN occurrence was very high in patients with specific, sometimes rare, SNP allele variants. 
In terms of clinical implications, genetic testing might help to identify a small proportion of 
patients at very high risk of FN who can be targeted with prophylactic measures. For the 
majority of patients, the current models do not reliably identify patients that will develop 
FN, but they do delineate patients who are unlikely to develop FN. This is clinically relevant 
since patients at low risk of FN probably do not need primary GCSF prophylaxis or nadir 
assessment, while the high-risk group is unpredictable and might need more extensive 
preventive measures or follow-up. 
The performance of any model tends to be highest in the training dataset. The results 
obtained with bootstrap resampling supported the internal validity of the FN in any cycle 
and the FN in first cycle models. The predictive ability of the models has yet to be tested 
in an entirely independent population, where model performance is usually lower. Before 
risk models are put to clinical use, true external validation is essential [134,196]. Another 
limitation of this study is the retrospective design; no detailed information was available on 
patient management in clinical practice, which is known to influence the risk of FN 
occurrence, and the reasons and timing of dose reductions and dose delays were not 
available. FN occurrence was not assessed according to chemotherapy cycle beyond the 
first cycle. GCSF was only administered to 15 patients before an event occurred due to 
stringent reimbursement criteria. Hence, the impact of GCSF on FN occurrence was 
difficult to assess.  
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To the best of our knowledge, this is the first study of risk of FN in the first and any cycle 
of chemotherapy in patients with early breast cancer that combined a set of patient- and 
chemotherapy-related factors with a large set of SNPs. Further validation studies are 
needed to confirm our findings, which should ideally be prospectively designed, sufficiently 
powered, and measure all possible predictors of FN occurrence reported in the literature. 
Approaches to clinical management that are measurable and known to influence the risk 
of FN occurrence, such as dose modifications or growth factor use before an FN event 
occurred, should be included. Information on SNPs should be available for as many 
patients as possible and the frequencies of possible genotypes of one SNP should be 
similar. Validated genetic factors have the potential to become reliable predictors of FN 
occurrence. The specific SNPs that were assessed in this study are independent from 
clinical decision-making and therefore less likely to be confounded by clinical practice. 
Conclusions  
We have identified a set of chemotherapy-related, patient-related, and genetic risk factors 
that predict occurrence of FN in the first and any cycle of chemotherapy in a large cohort 
of early breast cancer patients. Genetic effects in the models improved the predictive 
ability, but the overall predictive ability of the models remained poor. FN occurrence was 
very high in patients with specific SNP allele variants. Up-front genetic testing might be 
helpful to identify a limited group of very high-risk patients. Further independent validation 
is required to develop risk models that include genetic predictors of FN occurrence and 
can be used to personalise care. 
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Abstract 
Febrile neutropenia (FN) is a common and serious complication of chemotherapy 
treatment. Clinical risk models may help identify high risk FN patients but must undergo 
external validation before implementation in medical practice. Therefore, this study 
externally validated previously published clinical models of FN occurrence during 
chemotherapy in 240 non-Hodgkin lymphoma patients by using an independent 
observational dataset (N=1829). The models demonstrated predictive ability, and 
validation criteria for predicting any cycle FN were partially met but a larger than expected 
decrease in performance was noted (area under the receiver operating characteristic curve 
was 0.71 in the validation dataset and 0.83 in the training dataset). Age, weight, baseline 
white blood cell counts and planned chemotherapy parameters were confirmed to predict 
FN risk. Chemotherapy dose reductions, dose delays and colony-stimulating factor use 
were confirmed as risk modifiers during treatment. Further work is needed to improve the 
predictive ability of FN risk models. 
  
68 
 
 
  
Introduction 
Febrile neutropenia (FN) is a serious and frequent complication in cancer patients receiving 
chemotherapy that may necessitate hospitalizations and intravenous antibiotic treatment, 
affect treatment delivery and treatment success and increase short-term mortality 
[101,102,179]. In addition to the clinical consequences, FN in cancer patients can cause 
substantial hospitalization costs [197,198]. The majority of aggressive non-Hodgkin 
lymphoma (NHL) patients receive chemotherapy with cyclophosphamide, doxorubicin, 
vincristine and prednisone (CHOP) with or without rituximab (R) [96]. CHOP chemotherapy 
with a cycle length of 21 days showed FN rates of 20% or more and R-CHOP 
chemotherapy with a cycle length of 21 days showed rates close to 20%, in NHL patients 
under European routine practice conditions [97,98]. Dose dense (R-)CHOP regimens with 
a cycle length of 14 days have a substantially higher risk of neutropenic events and require 
routine administration of prophylactic colony-stimulating factor (CSF) [98,141]. 
Prophylactic CSF use is recommended by the European Organisation for Research and 
Treatment of Cancer (EORTC) and other international guidelines if the FN risk of a planned 
chemotherapy regimen is 20% or higher [98,141-143]. Effective targeting of CSF 
prophylaxis is particularly important for chemotherapy regimens with an FN risk of 10-20%, 
when patient risk factors must be incorporated into clinical decision making [98,141]. 
Antibacterial and antifungal prophylaxis have recently been recommended for neutropenic 
patients expected to have less than 100 neutrophils per μL for more than a week, or other 
risk factors for complications [144]. In patients with incurable cancer, FN risk may influence 
decisions on the continuation and choice of chemotherapy as well as treatment intensity. 
Numerous patient risk factors have been reported to increase the risk of FN including older 
age, low baseline blood cell counts, low serum albumin, anemia, abnormal bone marrow, 
increased lactate dehydrogenase (LDH), renal comorbidity, cardiovascular or hepatic 
disease, full dose or high-risk planned chemotherapy regimen and lack of CSF prophylaxis; 
and several neutropenia risk models in different cancers have been proposed [97,128,129]. 
Clinical risk models of FN occurrence with good predictive ability could play an important 
role in quantifying individual FN risk in cancer patients and targeting appropriate measures 
to high risk patients [127]. 
We previously developed risk models of FN in first and any cycle of chemotherapy using 
data on 240 NHL patients from the INC-EU (Impact of Neutropenia in Chemotherapy-
European Study Group) Prospective Observational European Neutropenia Study [105]. 
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The resulting models showed good test characteristics and we saw little degradation of 
model performance in internal 10-fold cross-validation, an approach that can be used if the 
available database is limited. However, before risk models can be put to clinical use they 
should undergo external validation in an independent dataset [134], but this occurs rarely 
[199]. Few neutropenia risk models have been validated using split-sample methods, i.e. 
dataset is randomly split-up into training set and validation set [113,130] and we are aware 
of only one partial validation using an independent dataset [108]. These more far-reaching 
validation efforts involved mixed tumor or breast cancer populations. Some of the 
associations found may hence be spurious or not applicable to the NHL setting. 
Therefore, we aimed to assess the ability of the INC-EU models to predict the FN risk of 
NHL patients on external data, using the independent, observational IMPACT NHL 
database. If successful, the INC-EU models might help identifying high risk versus low risk 
patients in clinical practice. 
Materials and Methods 
Characteristics of the INC-EU study and model 
The INC-EU Prospective Observational European Neutropenia Study was conducted in 
Belgium, France, Germany, Spain and the UK to assess the incidence and predictors of 
neutropenic events and reduced chemotherapy delivery for breast cancer and lymphoma 
patients undergoing chemotherapy [97,105,106]. The methodology of this study has been 
previously described [97]. IMPACT NHL (ClinialTrials.gov: NCT00903812) was a multi-
centre, retrospective and prospective, observational study of NHL patients receiving (R-
)CHOP chemotherapy. A total of 1864 patients were enrolled in 14 European countries 
and Australia to evaluate FN risk-assessment, FN occurrence and CSF use in routine 
medical practice; 1829 patients met all eligibility criteria [112,200]. Eligibility criteria were 
broad in both studies. Near-identity of patient characteristics was not required for the 
purpose of external validation as risk models should perform well in populations with 
partially different characteristics; otherwise their scope would be too narrow.  
The characteristics of the INC-EU models have been previously published [105]. 
Covariates were selected based on clinical and statistical grounds. Clinically relevant risk 
factors significantly associated with FN in cycle 1 of chemotherapy were older age, 
increasing planned cyclophosphamide dose, increasing planned etoposide dose, previous 
chemotherapy, recent infection and low baseline albumin. The same factors, with the 
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exception of previous chemotherapy and low baseline albumin, were also predictive of any 
cycle FN occurrence. Higher weight and prophylactic CSF use were protective factors in 
both models; antibiotic prophylaxis had no significant effect and was therefore excluded 
[105]. The following additional factors were statistically significant predictors of risk of any 
cycle FN: low baseline absolute neutrophil count (ANC) or white blood cell count (WBC), 
high baseline alkaline phosphatase, cardiovascular comorbidity and increasing planned 
cytarabine dose. Chemotherapy dose reductions and dose delays before an FN event 
occurred decreased the risk of FN. The INC-EU models demonstrated good apparent 
predictive ability; apparent in that performance was assessed directly in the dataset used 
to develop the models. Predictive ability was only slightly reduced under 10-fold cross 
validation conditions. 
Feasibility of comparing the INC-EU and IMPACT NHL studies was assessed. In the INC-
EU study, FN was defined as a temperature of ≥38.0˚C in conjunction with an ANC 
<0.5×109/L or WBC <1.0×109/L [105]. IMPACT NHL used a slightly broader definition as a 
neutrophil count ≤1.0×109/L was sufficient if predicted to fall below <0.5×109/L [112,200]. 
The exact time points of FN events were not directly available from the IMPACT NHL data. 
CSF use in the relevant chemotherapy cycles was therefore assumed to precede the FN 
event if it started on cycle days 1-7. Definitions of patient demographics or characteristics 
(used as covariates in the models) were reasonably similar or could be aligned by applying 
INC-EU definitions to IMPACT NHL.  
Covariates representing high baseline alkaline phosphatase (used in the INC-EU model of 
FN risk in any cycle) and recent infection were not available from the IMPACT NHL dataset. 
A sensitivity analysis using the INC-EU dataset investigated the effect of omitting these 
variables and showed that they contributed little to the risk models' overall predictive ability 
(area under the receiver operating characteristic (ROC) curve and test characteristics 
remained stable when they were excluded, as did the regression coefficients estimated for 
the other predictor variables). However, the most important predictors of FN such as age, 
previous chemotherapy, planned chemotherapy dose, CSF use, and baseline neutrophil 
counts were available for both study populations or could be derived from the IMPACT 
NHL dataset.  
External validation of the INC-EU models 
The external validation followed a double approach. First, we assessed the performance 
of the INC-EU risk models when applied to the IMPACT NHL database. The logistic 
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regression coefficients constituting the INC-EU models were combined with covariate 
values from the IMPACT NHL population. Linear predictors for risk of FN in cycle 1 and in 
any cycle were calculated for 1818 and 1675 IMPACT NHL patients, respectively, with no 
missing values for the relevant variables, and converted to predicted probabilities. These 
predicted probabilities for FN were compared with the patients' actual FN experience 
(occurrence yes versus no) in the first or any cycle of chemotherapy. Predictive ability was 
assessed by calculating the area under the ROC curve and test characteristics such as 
sensitivity, specificity, positive predictive value (PPV, proportion of patients classified as 
high risk by the model who actually have an event) and negative predictive value (NPV, 
proportion of patients classified as low risk by the model who actually have no event). Test 
characteristics were calculated at the optimal cut-off (i.e. the cut-off where sensitivity 
equals specificity) observed for both the INC-EU and IMPACT NHL datasets, and at a cut-
off of 0.5. We pre-specified that the risk models would be regarded as formally successfully 
validated if the sensitivity and specificity were no less than the observed values for the 
INC-EU dataset minus 10%, and if the area under the ROC curve was greater than 0.75 
(compared to 0.86 and 0.83 for the INC-EU dataset), based on the recommendations of 
published validation reports [201-203]. 
Second, to generate supplementary information, logistic regression coefficients were re-
estimated using the IMPACT NHL database, i.e. the effects deemed significant in the INC-
EU models were re-estimated from the IMPACT NHL data and compared with the original 
regression coefficient estimates. 
Results 
The INC-EU risk model was based on 240 NHL patients and the IMPACT NHL full analysis 
set used for validation included 1829 NHL patients. As presented in Table 4.3-1, the INC-
EU and IMPACT NHL populations showed similar treatment and patient characteristics. 
FN occurred in cycle 1 in 21 (9%) and in 127 (7%) patients in the INC-EU and IMPACT 
NHL studies, respectively, and was reported in any cycle FN in 53 (22%) and in 331 (18%) 
patients, respectively.  
Ability of the INC-EU models to predict FN in the IMPACT NHL database 
The INC-EU risk models predicted the occurrence of FN in cycle 1 and in any cycle in 
IMPACT NHL patients (Table 4.3-2). 
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Table 4.3-1: Baseline demographics and disposition of study population 
 IMPACT NHL 
(N = 1829) 
INC-EU* 
(N = 240) 
Tumor Type 
       Diffuse large B-cell lymphoma (DLBCL) 
       Follicular lymphoma (FL) 
       Other 
 
1136 (62%) 
345 (19%) 
348 (19%) 
 
154 (64%) 
35 (15%) 
51 (21%) 
Regimen received 
      CHOP-14 
      CHOP-21 
      Other 
 
536 (29%) 
1293 (71%) 
0 
 
41 (17%) 
178 (74%) 
21 (9%) 
Planned to receive Rituximab 1698 (93%) 196 (82%)  
Number of planned cycles 
      ≤4 cycles 
      5 - 6 cycles 
      >6 cycles 
 
239 (9%) 
1027 (56%) 
563 (31%) 
 
51 (21%) 
105 (44%) 
 84 (35%) 
Age  - mean (SD) 60.2 (13.9) 63.2 (12.9) 
Age≥65 years 805 (44%) 130 (54%) 
Female 803 (44%) 105 (44%) 
Ann Arbor Stage 3-4 1142 (62%) 133/237 (56%) 
International Prognostic Index (IPI) intermediate/high 849/1484 (57%) 162/237 (68%) 
FLIPI intermediate/High 251/345 (73%) not available 
Weight (kg) – mean (SD) 73.9 (15.5) 75 (16) 
Prior chemotherapy (chemo- and/or radiotherapy) 143 (8%) 25 (10%) 
Low baseline albumin <35 g/dl 
Missing baseline albumin 
254 (14%) 
628 (34%) 
54/188 (29%) 
52/240 (22%) 
Low baseline absolute neutrophil count<3 or WBC<5 377 (21%) 52/237 (22%) 
Cardiovascular comorbidities 398 (22%) 65 (27%) 
CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; FLIPI, Follicular Lymphoma International Prognostic 
Index; INC-EU, Impact of Neutropenia in Chemotherapy-European Study Group; NHL, non-Hodgkin lymphoma; WBC, 
white blood cell count 
* Based on INC-EU dataset and as reported in Pettengell, et al. 2009 [105]. 
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For FN in cycle 1, the area under the ROC curve was 0.64 (95% confidence interval [CI] 
0.59-0.69) (Figure 4.3-1) and 0.71 (CI 0.68-0.75) for FN in any cycle (Figure 4.3-1). In both 
cases, the lower confidence limit for the area under the ROC curve was significantly higher 
than 0.5, i.e. above the value that would indicate no predictive ability. Overall, 1074 out of 
1818 patients (59%) were classified correctly in the first cycle; 75 (4%) positively predicted 
patients experienced FN and 999 (55%) negatively predicted patients did not experience 
FN. Correct predictions in any cycle FN were higher; overall, 1113 patients out of 1675 
(66%) were correctly classified; 201 (12%) positively predicted patients experienced FN 
and 912 (54%) negatively predicted patients did not experience FN. These results were 
calculated using the optimal cut-off observed for the IMPACT NHL dataset (0.014 for FN 
in cycle 1 and 0.089 in any cycle). When the other cut-offs were used, test characteristics 
shifted towards lower sensitivity and higher specificity. When using a cut-off of 0.5, 
sensitivity was very low in the first cycle model (2%) and low in the any cycle model (18%), 
specificity was very high in both models (99% and 97%) and the NPV was 93% in the first 
cycle model and 85% in the any cycle model. 
Figure 4.3-1: ROC curves for FN in cycle 1 and FN in any cycle 
 
ROC, receiver operating characteristic 
Bisecting line indicates a discrimination that is no better than chance (ROC=0.5), no predictive ability 
Re-estimation of model parameters from the IMPACT NHL database 
When the model parameters of the first cycle INC-EU [105] FN model were re-estimated 
using the IMPACT NHL dataset, all effects maintained their original direction (with the 
exception of missing baseline albumin, a category that was introduced not to lose too many 
observations, as baseline albumin was not recorded for all patients), but some effect sizes 
75 
 
 
 
were substantially reduced (e.g. age, previous chemotherapy) and the majority of effects 
were not statistically significant (Table 4.3-3). The re-estimated model obtained an 
apparent area under the ROC curve of 0.67 (CI 0.62-0.72) compared to 0.86 (CI 0.79-0-
94) for the original INC-EU model of cycle 1 FN [105].  
In the any cycle model, all effects maintained their original direction and in this case effects 
remained statistically significant (with the exception of previous chemotherapy and 
cardiovascular comorbidity). Again, most effect sizes were reduced (Table 4.3-3). Planned 
cycle length, distinguishing dose-dense ([R-]CHOP-14) from standard chemotherapy 
delivery ([R-]CHOP-21), was not statistically significant in the INC-EU any cycle model but 
was statistically significant in the re-estimated model. The re-estimated model obtained an 
apparent area under the ROC curve of 0.74 (CI 0.70-0.77) compared to 0.83 (CI 0.76-0.90) 
for the corresponding INC-EU model of FN in any cycle [105]. 
Ad Hoc analysis of baseline albumin 
In the original INC-EU models [105], the effect of low baseline albumin was significant in 
the FN in cycle 1 model but failed to reach significance in the FN in any cycle model. In an 
unplanned ad hoc analysis it was assessed whether low baseline albumin would be 
predictive of FN in any cycle in the IMPACT NHL data. The addition of low baseline albumin 
as a covariate to the IMPACT NHL models confirmed an effect of low baseline albumin on 
the incidence of FN in any cycle. The resulting coefficient (OR = 1.80, CI 1.3-2.5) was 
highly significant. In light of this, the impact of including low baseline albumin in the 
published INC-EU model (FN in any cycle) on the ability to predict FN in the IMPACT NHL 
dataset was investigated. Little impact of adding low baseline albumin was seen and 
consequently the predictive ability of the modified algorithm was not substantially increased 
in comparison to the algorithm resulting from the published INC-EU model. 
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Discussion 
Models that identify and quantify individual FN risk factors can aid clinical practice and 
facilitate adherence to guideline recommendations. Our risk models for NHL patients 
demonstrated some ability to predict FN occurrence in cycle 1 and in any cycle of 
chemotherapy, in the entirely independent IMPACT NHL database. The observed high 
NPV (≥90%) relative to PPV is common to many risk models, here reflecting the ratio of 
patients without versus with FN (e.g., an overall FN incidence in the IMPACT study of 18% 
translates to a NPV of 82% in the absence of modelled risk assessment). However, formal 
pre-defined criteria for successful validation were not met for the cycle 1 model. The any 
cycle model, met criteria for sensitivity and specificity but not those for area under the ROC 
curve. The overall decrease in performance in the external validation dataset compared to 
the training dataset was larger than expected. Application to individual patients in routine 
practice would probably not achieve a sufficiently precise prediction of actual FN risk.  
A number of the covariates used in the original INC-EU models were confirmed to be 
important predictors of FN and are likely to be important elements of future (more refined) 
prediction models. These covariates included age, weight, low baseline ANC or WBC, 
planned chemotherapy cycle length and planned cyclophosphamide dose (where 
applicable). Chemotherapy dose reductions and delays, and CSF use were confirmed as 
important modifiers of FN risk during the course of chemotherapy. They can decrease the 
risk of FN in subsequent cycles with impact on the overall risk, but their use is often 
triggered by the observed or anticipated FN risk in early cycles. Effects of previous 
chemotherapy (incidence of previous chemotherapy was <10% in both the INC-EU and 
the IMPACT NHL data) and cardiovascular comorbidity could not be confirmed. The 
capture of cardiovascular comorbidity data in IMPACT NHL was not well standardized; only 
system organ class comorbidity data were collected without including further details on 
specific disease states. Consequently, the potential for correctly assessing the impact of 
these covariates may have been limited. Low albumin is representative of poor nutritional 
condition. An unplanned extension of our external validation analyses suggested that low 
baseline albumin may be an influential contributor to the risk of FN. Although its impact on 
the predictive ability of the models was limited, clinical decision making should possibly 
take this element into account when assessing patient risk factors. The true effect of low 
baseline albumin warrants further investigation.  
The predictive ability of the original INC-EU models of FN occurrence, when applied to 
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independent lymphoma datasets, is unlikely to be sufficient for effective prediction. As 
validated risk models of FN occurrence in NHL patients and other cancer patients are rare, 
there is a lack of materials our results can be compared with. The apparent predictive ability 
of our models resembled that of a model recently published by Lyman, et al., in which risk 
of severe and febrile neutropenia in cycle 1 was assessed in patients with solid tumors and 
malignant lymphomas [130]. These authors reported an apparent NPV of 96% and PPV of 
34%. Within-study 2:1 random split-sample validation resulted in a slightly increased PPV 
(36%) but lower NPV (93%). The fact that our validation study used data on NHL patients 
enrolled into an entirely different study may explain the much larger performance change 
seen in our case [130,204]. A risk model developed by López-Pousa, et al. [131] for first 
cycle chemotherapy-induced neutropenia in 1194 patients with solid tumors had slightly 
lower apparent predictive ability (PPV of 17% and NPV of 94%) than our model. To our 
knowledge, this model has not been validated externally. The observed differences in 
model performance under different conditions and especially the difference in performance 
change that may result from the use of random split-sample validation versus true external 
validation confirms the importance of the latter approach before risk models are put to 
clinical use. 
Using prospectively collected data (in the INC-EU study and part of the IMPACT NHL 
study) to develop and validate prognostic models may add strength as such data may be 
more reliable than retrospectively collected data. Possible limitations of our work include 
the small training dataset sample size (N = 240), the mixture of first line and relapsed 
chemotherapy patients with different treatment histories (although ≤10% in both datasets 
had previous chemotherapy) and treatment intensity, slight differences in some definitions 
between the IMPACT NHL study and the INC-EU study and unavailability of two covariates 
of limited relevance in IMPACT NHL. However, we consider only the limited size of the 
training set has possibly contributed to the decrease in performance. Another possible 
explanation could be the lack of accounting for other, unknown prognostic covariates such 
as biological or genetic risk factors [205]. In addition, correct representation of the 
neutropenic potential of combination chemotherapy regimens remains a challenge. The 
dosage of the individual components is often correlated (e.g. patients with higher body 
surface area get a proportionally higher dose of each substance). This makes it difficult to 
correctly estimate the risk associated with each individual agent. Moreover, agents are 
used in different combinations (although not so much here where CHOP was 
predominantly used); to our knowledge, their interaction has not been systematically 
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studied in routine practice populations, with a focus on implications for FN risk. An 
additional issue that arises when risk models are put to clinical use is choice of cut-off 
value. Related decision making cannot be solely based on statistical criteria. For example, 
the main clinical focus may be on high PPV (i.e. selection of a patient group that certainly 
needs prophylaxis) or rather on high NPV (i.e. selection of a patient group where 
prophylaxis can be safely omitted). 
The current study indicates that the efficient identification of patients at high risk of FN 
continues to face serious challenges. Additional strategies are required for future research 
before FN risk models can be incorporated into routine clinical practice. As a first step, 
systematic literature reviews (documenting all currently proposed FN risk factors with 
supporting evidence), hypothesis-driven reanalyses of existing data, and, where required, 
well-defined primary data collections should be used to define the most promising 
elements. These elements should be consistent with our knowledge of the pathophysiology 
of chemotherapy-induced FN, or at least repeatable in independent clinical studies. 
Additional criteria would include high predictive ability and easy applicability in routine 
practice situations. The resulting set of candidate predictors would inform thorough, 
sufficiently powered, prospective cohort studies generating comprehensive datasets for 
risk model generation and validation. Under ideal circumstances, additional clinical and 
health economic evidence for the resulting prediction models would be obtained from 
randomized controlled studies comparing standard medical strategies with medical 
strategies dependent on predicted individual risk [206]. The primary endpoint of FN 
occurrence should be complemented with secondary endpoints including FN-related 
mortality and hospitalisation for FN. In the real-world, feasibility aspects and timeliness 
may require more limited approaches. 
It should additionally be noted that even validated risk models would only affect patients’ 
health outcomes if they influenced physicians’ treatment decisions [207]. Salar, et al. [112] 
showed that although in the IMPACT NHL population about 60% of the patients were 
assessed as being at high risk of FN, less than half received primary prophylactic CSF as 
per guideline recommendations [98,141,143,142], indicating that there is an additional risk 
assessment done by physicians. As some guideline recommendations remain rather 
vague, risk models could be expected to provide clearer guidance for distinguishing high 
risk from low risk patients. Even models with limited predictive ability may make physicians 
more aware of relevant risk criteria. Comparative studies evaluating how the availability of 
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risk models influences physician behaviour and health outcomes [207] might help to 
promote evidence-driven risk prediction and optimize clinical and supportive care together 
with physicians’ decision making on chemotherapy use, patient surveillance and the need 
for prophylaxis. 
The limited performance of our risk models highlights the importance of careful clinical 
decision making until validated models are available with adequate predictive ability. 
Therefore, there is a clear need for further studies and continuing validation of proposed 
risk predictors and tools. 
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Abstract  
Purpose: Pegfilgrastim was introduced over a decade ago. Other long-acting granulocyte 
colony-stimulating factors (G-CSFs) have recently been developed. We systematically 
reviewed the efficacy, effectiveness and safety of neutropenia prophylaxis with long-acting 
G-CSFs in cancer patients receiving chemotherapy.   
Methods: We performed a systematic literature search of the MEDLINE, EMBASE and 
Cochrane Library databases, and abstracts from key congresses. Studies of long-acting 
G-CSFs for prophylaxis of chemotherapy-induced neutropenia (CIN) and febrile 
neutropenia (FN) were identified by two independent reviewers. Abstracts and full texts 
were assessed for final inclusion; risk of bias was evaluated using the Cochrane’s tool. 
Effectiveness and safety results were extracted according to study type and G-CSF used.  
Results: Of the 839 articles identified, 41 articles representing different studies met the 
eligibility criteria. In five randomised controlled trials, 11 clinical trials and 17 observational 
studies across several tumor types and chemotherapy regimens, pegfilgrastim was used 
alone or compared with daily G-CSF, no G-CSF, no upfront pegfilgrastim, or placebo. 
Studies generally reported lower incidence of CIN (4/7 studies), FN (11/14 studies), 
hospitalisations (9/13 studies) antibiotic use (6/7 studies), and adverse events (2/5 studies) 
with pegfilgrastim than filgrastim, no upfront pegfilgrastim or no G-CSF. Eight studies 
evaluated other long-acting G-CSFs; most (5/8) were compared to pegfilgrastim and 
involved patients with breast cancer receiving docetaxel-based therapy. Efficacy and 
safety profiles of balugrastim and lipegfilgrastim were comparable to pegfilgrastim in phase 
3 studies. Efficacy and safety of other long-acting G-CSFs were mixed. 
Conclusions: Pegfilgrastim reduced the incidence of FN and CIN compared with no 
prophylaxis. Most studies showed better efficacy and effectiveness for pegfilgrastim than 
filgrastim. Efficacy and safety profiles of lipegfilgrastim and balugrastim were similar to 
pegfilgrastim. 
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Introduction  
In patients with cancer receiving cytotoxic chemotherapy, chemotherapy-induced 
neutropenia (CIN) and febrile neutropenia (FN) are frequent complications. CIN is graded 
according to severity of the reduction of the absolute neutrophil count (ANC) and FN is 
commonly defined as ANC <0.5 x 109/L with an oral temperature ≥38°C for more than 1 
hour [142]. Patients experiencing neutropenic events are more susceptible to subsequent 
infections [99]. As a consequence of FN, patients often require hospitalisation and 
antibiotic treatment and frequently have their chemotherapy dose reduced or delayed 
[103,208]. Modifications to chemotherapy may decrease its effectiveness, thereby 
potentially compromising treatment outcomes [103].  
Granulocyte colony-stimulating factors (G-CSFs) stimulate the production and maturation 
of neutrophils during chemotherapy and reduce the incidence and duration of CIN and 
incidence of FN [139,209]. Prophylactic G-CSF use from the first cycle of chemotherapy is 
recommended by the European Organisation for Research and Treatment of Cancer 
(EORTC) [98] and other international guidelines [141-143] if the planned chemotherapy 
regimen is associated with an FN risk of 20% or more. For chemotherapy regimens with 
an intermediate FN risk of 10–20% guidelines recommend that patient-related and 
disease-related factors should also be considered when deciding whether or not to give G-
CSF support. 
Daily G-CSFs are primarily cleared through the kidneys and require dosing until recovery 
of the neutrophil count. Long-acting G-CSFs are primarily cleared by neutrophils and have 
significantly reduced renal clearance compared with daily G-CSFs. They therefore require 
only a single dose per chemotherapy cycle. Pegfilgrastim (Neulasta®, Amgen Inc., CA, 
USA), consisting of the human recombinant G-CSF filgrastim pegylated at the N-terminus 
with a 20 kilodalton polyethylene glycol molecule, is administered subcutaneously as a 
single 6 mg dose [210]. It was approved in both the USA and Europe in 2002. 
Lipegfilgrastim (Lonquex®, Teva Pharma B. V.), a long-acting filgrastim molecule that is 
pegylated at a different site from pegfilgrastim, was approved in Europe in 2013 [211]. 
Other long-acting G-CSFs, such as balugrastim, are in clinical development [212]. 
The emergence of these recently-developed long-acting G-CSFs necessitates a re-
evaluation of the evidence. Direct comparative data are limited, and there are no 
systematic reviews of long-acting G-CSFs that include data from both observational 
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studies and randomised controlled trials (RCTs). Therefore, we conducted a systematic 
review to capture the available data on the efficacy, safety and effectiveness of long-acting 
G-CSFs for prophylaxis of CIN and FN in adult patients with cancer. 
Methods  
Study design  
The systematic review was performed according to a pre-specified protocol that was 
agreed by all authors. We searched the following electronic databases: MEDLINE In-
Process & Other Non-Indexed Citations and OVID MEDLINE 1948-present, EMBASE 
1980-present and the Cochrane Library. A search of abstract books was also conducted 
from the annual meetings of the American Society of Clinical Oncology, the American 
Society of Hematology, the European Hematology Association, the European Society for 
Medical Oncology, the European Multidisciplinary Cancer Congress, the International 
Society for Pharmacoeconomics and Outcomes Research and the Multinational 
Association of Supportive Care in Cancer. Complete search strings are listed in Appendix. 
The electronic database searches included articles published up to April 2013 and were 
restricted to English-language studies. Conference abstracts were limited to those 
published between January 2009 and April 2013. This report follows the PRISMA 
statement for reporting systematic reviews and meta-analyses [150]. 
Study Selection  
Initially, two independent reviewers screened the titles and abstracts of the search results 
for studies of human adult haematology or oncology patients who were receiving long-
acting-G-CSF primary prophylaxis to reduce the risk of CIN during chemotherapy. Studies 
in which patients received bone marrow transplantation were excluded. Clinical trials and 
observational studies were included. Editorials, letters, case reports, guidelines, health 
technology assessment reports, economic evaluations, narrative reviews and research 
protocols were excluded. Papers were excluded if they did not report neutropenia-related 
outcomes. Full texts of the remaining articles were then assessed by the reviewers for final 
inclusion. Additional exclusion criteria were applied at this second stage: studies 
comparing pegfilgrastim with a daily G-CSF, placebo or no prophylaxis were excluded if 
fewer than 50 patients received pegfilgrastim; studies with pegfilgrastim alone (which 
therefore allowed no comparisons) were excluded if fewer than 100 patients received 
pegfilgrastim. Studies in which pegfilgrastim was used outside of its approved indication 
were excluded. These additional exclusion criteria were not applied to studies involving 
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new long-acting G-CSFs because we expected to find far fewer papers on these and 
wanted to ensure that all available data on these other agents were captured. Papers or 
abstracts reporting results from the same study were indicated as such. If a study included 
in the form of a congress abstract was published as a peer-reviewed paper after our 
literature search, we included the paper in place of the congress abstract.  
Data extraction  
The data collection comprised study and patient characteristics, efficacy (effect of a 
treatment under controlled, clinical trial conditions), effectiveness (effect of a treatment 
under uncontrolled, real-world conditions) and safety. Detailed definitions of outcome 
measures are listed in Appendix.  Studies were classified according to their design: ‘RCTs’ 
where patients were randomised to G-CSFs; clinical trials in which patients were not 
randomly assigned to neutropenia prophylaxis or no treatment were termed ‘clinical trials’; 
and studies of routine clinical practice were termed ‘observational studies’. Evidence found 
in the literature was extracted as presented by the original authors of the study.  
Risk of bias assessment 
Two independent reviewers assessed risk of bias; disagreements were resolved within the 
reviewer team by consensus. RCTs were assessed using the Cochrane Collaboration’s 
assessment tool [213]. Non-randomised studies were assessed using the Methods Guide 
for Comparative Effectiveness Reviews of the US Agency for Healthcare Research and 
Quality [214]. Six domains of bias (selection bias, performance bias, detection bias, attrition 
bias, reporting bias and other bias) were assessed. Based on the reviewers' judgments, 
every article was rated as having a ‘low’, ‘high’ or ‘unclear’ risk of bias. Risk of bias was 
not assessed for conference abstracts.  
Results 
Eligible trials and study characteristics 
Our search identified 731 full publications and 108 congress abstracts (Figure 4.4-1). After 
removing duplicates, 700 items were left, of which 482 were excluded on the basis of title 
and abstract screening, leaving 218 articles (Supplementary material of the journal, ESM 
3). Three relevant articles were published after completion of the search: Bondarenko et 
al. (2013) [215], Almenar-Cubells et al. (2013) [216] and Volovat et al. (2013) [217]; these 
were included to replace congress abstracts identified by the initial search that described 
the same studies [218-220].   
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Figure 4.4-1: PRISMA flow diagram 
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Finally, 33 publications and 11 congress abstracts representing 41 studies were analysed. 
Key characteristics of the included studies are presented in Table 4.4-1. 
Figure 4.4-2 illustrates the number of patients exposed to each of the included substances 
or treatment strategies, the G-CSF interventions used, and the study design. The studies 
included 13 that looked at pegfilgrastim alone, 15 studies in which pegfilgrastim was 
compared with a daily G-CSF, three studies in which pegfilgrastim was compared with 
placebo and two studies in which pegfilgrastim primary prophylaxis was compared with no 
pegfilgrastim primary prophylaxis. We found eight studies that compared other long-acting 
G-CSFs with daily G-CSFs, pegfilgrastim, or placebo. The number of patients who received 
a long-acting G-CSF was 50,089 (pegfilgrastim = 49,207; lipegfilgrastim = 505; balugrastim 
= 281; Maxy-G34 = 27; Ro 25-8315 = 28; BCD-017 = 41). 
Pegfilgrastim studies included patients with breast, lung, colorectal or gastro-esophageal 
cancer, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, acute myeloid leukaemia and 
various other solid tumours. These studies included patients taking 12 standard 
chemotherapy regimens and numerous non-standard regimens. All studies of newer long-
acting G-CSFs except one (which looked at lipegfilgrastim in non-small-cell lung cancer 
[221]) were conducted in patients with breast cancer, most of whom were receiving 
docetaxel and doxorubicin. 
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ra
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ra
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 m
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ra
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 C
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ra
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 m
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ra
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ra
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 m
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at
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ra
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ra
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 m
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 d
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ra
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Risk of bias assessment 
Risk of bias was typically higher in non-randomized trials and observational studies than 
in RCTs (Figure 4.4-3). Most studies excluded patients receiving concomitant antibiotic 
prophylaxis or who had previously received chemotherapy; therefore, risk of performance 
bias was low. Risk of reporting bias was difficult to assess across all types of studies 
because the study protocols were not published. 
Figure 4.4-3: Risk of bias of included studies 
a) Randomised controlled trials (RCTs) 
are defined as those studies in which 
patients were randomised to a granulocyte 
colony-stimulating factor (G-CSF). 
Adequate sequence generation and 
allocation concealment refers to selection 
bias, blinding of participants and staff to 
performance bias, blinding of outcome 
assessors to detection bias, incomplete 
outcome data to attrition bias and selective 
outcome reporting refers to reporting bias. 
 
 
   
b) Non-randomised clinical trials are those in which patients were not randomised to a granulocyte colony-stimulating 
factor (G-CSF). The risk of bias assessment includes non-randomised clinical trials and observational studies that 
included more than one granulocyte colony-stimulating factor. c) The risk of bias assessment includes non-randomised 
clinical trials and observational studies that included pegfilgrastim only. 
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Efficacy and effectiveness of pegfilgrastim 
Table 4.4-2 shows efficacy and effectiveness endpoints for studies of pegfilgrastim alone 
or compared with daily-G-CSFs, placebo or no treatment.  
Incidence of FN 
Three RCTs reported a significant reduction in FN for pegfilgrastim versus placebo (1% vs 
17% [228], 2% vs 6% [229,230], and 2% vs 8% [231]) in patients with breast or colorectal 
cancer receiving chemotherapy regimens associated with various FN risk profiles. One 
RCT designed to demonstrate non-inferiority in duration of severe neutropenia reported a 
significant reduction in FN incidence for pegfilgrastim versus filgrastim (9% vs 18%) in 
patients with breast cancer [225]. Another RCT with a similar design found a non-significant 
trend towards lower FN incidence for pegfilgrastim versus filgrastim (13% vs 20%) [224].  
Ten clinical trials reported FN incidence across numerous tumor and chemotherapy types, 
including several dose-dense regimens. In eight of these trials all patients received 
pegfilgrastim; FN incidence ranged from 1–10% [233,235,236,239-243]. A study in which 
FN prophylaxis was changed by protocol amendment in subsequent cohorts of patients 
with primary breast cancer treated with a high FN-risk regimen (docetaxel, doxorubicin and 
cyclophosphamide), found a significant reduction in the incidence of FN for pegfilgrastim 
versus daily G-CSF (7% vs 18%) [238]. In contrast, another breast cancer trial in which G-
CSF schedules were selected at the physician’s discretion reported a higher FN incidence 
for pegfilgrastim versus filgrastim (11% vs 4%) [234]. 
Observational studies showed FN incidence was higher among patients with 
haematological malignancies (14–16%) [246,247] than in those with solid tumors (4–12%) 
[216,249,250,252,253,256,257]. Five of these observational studies that reported FN 
incidence compared neutropenia prophylaxis: two studies across various tumor types 
reported trends towards reduced FN incidence with pegfilgrastim versus daily G-CSF (11% 
vs 24% and 7% vs 13%, respectively) [216,253], one found a significant reduction (5% vs 
7%) [257]; and two did not find a difference for pegfilgrastim versus filgrastim in Non-
Hodgkin’s lymphoma (NHL) [246] and breast cancer [251]. Significant reductions in FN 
incidence for pegfilgrastim primary prophylaxis versus no pegfilgrastim primary prophylaxis 
were also seen in observational studies of patients with breast cancer (4% vs 30%) and in 
patients with various tumour types (odds ratio [95% confidence interval (CI)]: 0.49 [0.34–
0.68]) [111,249],  
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Incidence of CIN 
An RCT in patients with colorectal cancer treated with chemotherapy with a low FN risk 
(FOLFOX, FOLFIRI or FOIL) found pegfilgrastim significantly reduced CIN incidence 
compared with placebo (13% vs 43%) [231]. RCTs comparing pegfilgrastim with filgrastim 
in a non-inferiority setting reported no significant difference in CIN incidence in patients 
with breast cancer receiving chemotherapy associated with a high FN risk [224,225].  
In clinical trials investigating dose-dense regimens, CIN incidence with pegfilgrastim was 
low and ranged from 3-11% in patients with breast cancer [233,236,239] and 34% in 
gastro-esophageal cancer [241]. In studies of standard-dose chemotherapy regimens 
across various tumour types CIN incidence ranged from 22% to 30% [242,243]. One trial 
reported that pegfilgrastim significantly reduced the incidence of CIN compared with daily 
G-CSF (37% vs 58%) in patients with breast cancer [238]. 
Three observational studies reporting CIN incidence compared neutropenia prophylaxis; a 
difference was not found between pegfilgrastim and filgrastim in patients with breast cancer 
[251], but in patients with various tumours or NHL CIN incidence was lower in those 
receiving pegfilgrastim than those receiving daily G-CSF (28% vs 49% and 41% vs 50%) 
[216,248]. 
Incidence of hospitalisations due to CIN or FN 
One RCT reported a significant reduction in FN-related hospitalisations in patients with 
breast cancer who received pegfilgrastim versus placebo (1% vs 14%) [228], while another 
in patients with colorectal cancer found no significant difference in CIN-related 
hospitalisations [231].  
In a clinical trial including patients with various tumour types receiving pegfilgrastim primary 
prophylaxis in community-based practices in the USA, the incidence of FN-related 
hospitalisations was 4% [243]. A similar study in elderly patients found the incidence of 
CIN- or FN-related hospitalisations was 5% [242]. Two clinical trials of patients with breast 
cancer found no significant difference in incidence and duration of FN-related 
hospitalisations between pegfilgrastim and daily G-CSFs [234,238]. 
Three retrospective observational studies enrolling patients with various tumour types 
found trends towards reduced incidence of hospitalisations due to FN for pegfilgrastim 
versus daily G-CSF (9% vs 20%, 3% vs 11% and 3% vs 7%) [216,253,258], whereas 
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another found no significant difference between sargramostim and pegfilgrastim [254]. Two 
other retrospective observational studies [259,260], reported significant decreases in the 
risk of CIN-related hospitalisations for pegfilgrastim compared with filgrastim (1% vs 4% 
and 1% vs 2%); findings supported by a study of two US databases that found pegfilgrastim 
reduced the risk of neutropenia-related hospitalisation compared with filgrastim [255]. 
Incidence of chemotherapy dose reductions and delays 
In one RCT in patients with breast cancer receiving pegfilgrastim or placebo, there was no 
significant difference in the proportion of patients receiving their full chemotherapy dose on 
schedule [228]; however, cross-over from the placebo to the pegfilgrastim arm was allowed 
if FN occurred. Another RCT in colorectal cancer reported a significant decrease in dose 
reductions (3% vs 11%) and delays (4% vs 20%) due to neutropenia for pegfilgrastim 
versus placebo [231].  
There was a wide range of incidence of dose delays and reductions in the clinical trials 
(2%–77% and 2%–33%, respectively), but most papers did not specify whether or not the 
chemotherapy modifications were due to neutropenia [234,236,241,243]. Only one clinical 
trial compared the incidence of dose delays (due to FN events and non-haematological 
toxicity) with pegfilgrastim and filgrastim in patients with breast cancer. It found no 
significant difference between the two arms [234]. 
Rates of dose delays and reductions in observational studies also varied considerably 
between trials (5%–55% and 5%–42%, respectively) [216,246,247,249,252,253]. One 
study found a significantly lower incidence of delays for pegfilgrastim primary prophylaxis 
versus no pegfilgrastim primary prophylaxis in patients with breast cancer (5% vs 12%), 
but found no significant difference in dose reductions [249]. In two studies of patients with 
various tumour types, fewer dose delays (42% vs 55%) [216] and dose reductions (32% 
vs 38% and 7% vs 21%) [216,253] due to neutropenia for pegfilgrastim versus daily G-
CSF were observed. In a population of Asian patients with NHL, rates of dose reductions 
and delays were slightly higher in patients who received pegfilgrastim than in those who 
received filgrastim [246]. 
Antibiotic use 
In one RCT, a non-significant reduction in antibiotic use was reported for pegfilgrastim 
versus filgrastim (17% vs 21%) in patients with breast cancer [224]. Two RCTs reported a 
significant reduction in the use of antibiotics due to FN for pegfilgrastim versus placebo, 
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one in breast cancer (2% vs 10%) [228] and one in colorectal cancer (2% vs 7%) [231].   
A clinical trial in breast cancer found no significant difference in the use of antibiotics 
between patients receiving pegfilgrastim and filgrastim (11% vs 4%) [234]. 
An observational study found a significant reduction in the use of antibiotics for 
pegfilgrastim primary prophylaxis versus no pegfilgrastim primary prophylaxis (28% vs 
46%) in patients with breast cancer [249]. Two observational studies in patients with 
various tumour types found lower rates of FN-related antibiotic use in patients who 
received pegfilgrastim than those receiving daily G-CSF (4% vs 11% and 8% vs 17%); in 
the former study, this difference reached significance [216,253]. 
Safety of pegfilgrastim 
Table 4.4-2 shows safety endpoints for studies of pegfilgrastim alone or compared with 
daily-G-CSFs, placebo or no treatment. 
All G-CSF-related adverse events  
Two RCTs in patients with breast cancer reported that G-CSF-related adverse events 
(AEs) were similar for pegfilgrastim and filgrastim [224,225]. Another RCT found a non-
significant increase in G-CSF-related AEs for pegfilgrastim compared with placebo (11% 
vs 1%) in patients with colorectal cancer, primarily due to increased bone pain [231]. 
Pegfilgrastim-related serious AEs were also infrequent (0.5%) in patients with various 
tumors in a clinical trial [243]. Two observational studies in patients with various tumors 
reported a non-significant decrease in G-CSF-related AEs for pegfilgrastim versus daily G-
CSF (6% vs 10% and 1% vs 5%) [216,253]. None of the studies reported any fatal AEs 
that were attributed to G-CSF prophylaxis. 
Musculoskeletal pain 
In two placebo-controlled RCTs including patients with breast or colorectal cancer, 
occurrence of any-grade musculoskeletal pain was higher in the pegfilgrastim arms than 
the placebo arms (31% vs 27% and 11% vs 1%) [228,231]. In two further RCTs of patients 
with breast cancer randomized to pegfilgrastim or filgrastim, overall rates of bone pain were 
comparable between arms [224,225], and severe bone pain appeared reduced for 
pegfilgrastim versus filgrastim (1% vs 8%) [224].  
In five non-comparative clinical trials, the incidence of any-grade musculoskeletal pain with 
pegfilgrastim reported ranged from 7% to 26% [233,242] and the incidence of severe 
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musculoskeletal pain ranged from 0% to 9% [233,236,239,243] across patients with breast 
cancer and various tumour types.  
In general, the reported incidence of musculoskeletal pain was lower in observational 
studies than in clinical trials. The incidence of any-grade musculoskeletal pain with 
pegfilgrastim in observational studies varied, from 6% in one study where all patients 
received pegfilgrastim (with no patients experiencing serious bone or muscle pain) [256], 
to 50% in patients receiving either pegfilgrastim or filgrastim [251]. In two other 
observational studies of patients with various tumor types that compared pegfilgrastim with 
daily G-CSF, bone pain was less common in the pegfilgrastim arms (2% vs 6% and 1% vs 
3%) [216,253].  
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aPatients with FN received open-label pegfilgrastim 
bThe three groups receiving different schedules of filgrastim were combined to one ‘filgrastim’ group 
cOnly the patients randomized to receive pefilgrastim on day 2 were included 
dPatients receiving concomitant ciprofloxacin (n = 567) were excluded from this review 
ePatients receiving pegfilgrastim at physician discretion (n = 416) were excluded 
f185 patients received prophylactic antibiotics 
Other long-acting G-CSFs 
Table 4.4-3 shows the efficacy and safety endpoints for studies involving other long-acting 
G-CSFs. 
Lipegfilgrastim 
Lipegfilgrastim is pegylated at a different site from pegfilgrastim (threonine 134) using a 
carbohydrate linker involving two enzymatic steps. In a placebo-controlled RCT in patients 
with lung cancer, there was no statistically significant reduction in the first-cycle incidence 
of FN compared to placebo (2% vs 6%) and a significant reduction in the first-cycle 
incidence of severe neutropenia (32% vs 59%) [221]. G-CSF-related AEs were more 
common in the lipegfilgrastim arm (14% vs 10%) [221]. In a non-inferiority RCT comparing 
lipegfilgrastim with pegfilgrastim in patients with breast cancer, there was no significant 
difference in FN incidence (1% vs 3%), and a non-significant reduction in severe 
neutropenia incidence (44% vs 51%) [215]. Rates of FN-related hospitalizations and 
antibiotic use were also comparable between the two study arms (1% vs 2% and 1% vs 
3%, respectively) [215]. AEs, including bone pain (14% vs 10%), myalgia (9% vs 6%) and 
arthralgia (5% vs 2%), were slightly more common with lipegfilgrastim than with 
pegfilgrastim, but the difference was not significant [215]. In a second RCT in breast 
cancer, duration of severe neutropenia for lipegfilgrastim and pegfilgrastim was reported 
to be similar [222].  
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Balugrastim 
Balugrastim is a non-pegylated recombinant fusion protein composed of human serum 
albumin and G-CSF harvested from yeast. It has been investigated at a dose of 40 mg in 
two RCTs in patients with breast cancer treated with doxorubicin and docetaxel. In one, 
incidence (58% vs 59%) and duration (1.1 days vs 1 day) of severe neutropenia in cycle 1 
were similar for balugrastim and pegfilgrastim [217]. There was no significant difference in 
FN incidence in cycle 1 between balugrastim and pegfilgrastim (1% vs 3%). The frequency 
of treatment-related AEs was similar for balugrastim and pegfilgrastim (20% vs 19%) [217]. 
The second RCT found similar durations of severe neutropenia for balugrastim and 
pegfilgrastim (1.3 days vs 1.2 days) [218]. 
BCD-017, Maxy-G34 and Ro 25-8315 
BCD-017 (empegfilgrastim), Maxy-G34 and Ro 25-8315 are all covalent conjugates of 
recombinant human G-CSF and polyethylene glycol. Small RCTs compared BCD-017 and 
Ro 25-8315 with filgrastim in patients with breast cancer but found that neutropenia-related 
outcomes, including rates of FN, were generally lower in the filgrastim arms [226,227]. 
Safety data were reported in the Ro 25-8315 study and suggest G-CSF-related AEs are 
more common with Ro 25-8315 than with filgrastim [227]. Maxy-G34 was compared with 
pegfilgrastim in a clinical trial. The incidence of FN and duration of CIN were similar in the 
two study arms [237]. No safety data were reported. 
Discussion 
To our knowledge, this is the only systematic review of long-acting G-CSFs that includes 
newly developed agents and data from both clinical trials and observational studies. We 
identified 12 RCTs, 12 clinical trials and 17 observational studies, including 58,342 patients 
in total. Studies in patients with breast cancer were dominant, partly because these were 
the registration studies for the G-CSFs.  
Pegfilgrastim studies included a range of patient populations, cancer types and stages, 
and chemotherapy regimens. Efficacy and effectiveness results were generally consistent. 
Although pegfilgrastim did not uniformly show better efficacy or effectiveness in all studies, 
the vast majority showed better efficacy or effectiveness compared to daily G-CSF, no 
upfront pegfilgrastim, no G-CSF or placebo in terms of reduction of the incidence of CIN 
(4/7 studies), FN (11/14 studies), chemotherapy dose delays and reductions (6/8 studies), 
antibiotic use (6/7 studies) and neutropenia-related hospitalizations (9/13 studies). The 
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observed variation may be partly explained by differences in patient populations and 
cancer types, or in the way G-CSF was administered. Thirteen (35%) studies of 
pegfilgrastim reported safety data and most of these focused on musculoskeletal pain; only 
three studies reported other G-CSF-related AEs. This suggests that the safety profile of G-
CSFs may be generally accepted and studies now investigate only specific AEs known to 
be associated with their use. The incidence of G-CSF-related AEs was similar between 
pegfilgrastim and filgrastim. The incidence of bone pain and severe bone pain was lower 
or no different for pegfilgrastim than filgrastim in most RCTs and observational studies (4/6 
studies).  
Previously published systematic reviews and meta-analyses of RCTs comparing 
pegfilgrastim with daily G-CSF or placebo by Cooper et al. and Pinto et al. found that 
pegfilgrastim more effectively reduced the incidence of FN [261,262]. The RCT reported 
by Decaestecker et al. and Pinter et al. [229,230], showing better efficacy for pegfilgrastim 
than placebo in reducing the incidence of neutropenia in colorectal cancer patients, 
reported in this systematic review was not included in these previous systematic reviews. 
We additionally included non-randomized clinical trials and observational studies that have 
not been included in former systematic reviews [261,262]. Nevertheless, the results of our 
systematic review are generally consistent with these studies. However, while well-
designed RCTs have a low risk of bias, inclusion criteria can be restrictive. The 
observational studies included in our review indicate an advantage for pegfilgrastim over 
daily G-CSFs or no treatment, suggesting that the efficacy of pegfilgrastim demonstrated 
in clinical trials has been translated into clinical practice. In fact, we found a greater 
magnitude of reduction in CIN incidence with pegfilgrastim versus filgrastim in 
observational studies than RCTs; this could be due to a shorter duration of G-CSF use in 
current practice (e.g. 5–6 days in clinical practice vs 10–11 days in clinical trials) [98]. 
Importantly, the safety data from observational studies were consistent with data from 
RCTs, suggesting that the pegfilgrastim safety profile can be used to guide treatment in a 
broad patient population. However, care should be taken when interpreting the results of 
observational studies, owing to the higher risk of bias and confounding factors. 
Almost all the studies including other long acting G-CSFs were RCTs of patients with breast 
cancer (7/8 studies) receiving doxorubicin and docetaxel (5/8 studies). Lipegfilgrastim has 
been the most extensively tested (3/8 studies) and appears to be similar to pegfilgrastim 
regarding the reduction in duration of severe neutropenia in patients with breast cancer. 
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Efficacy of lipegfilgrastim in reducing the incidence of FN was not statistically superior to 
placebo in a congress abstract describing an RCT in patients with lung cancer [221]. 
Lipegfilgrastim has now been approved in Europe for reducing the incidence and duration 
of FN in adults with cancer who are receiving cytotoxic chemotherapy [211]. Further clinical 
and observational studies in a wider range of tumor types and chemotherapy regimens will 
confirm whether its efficacy and safety is maintained across a broader patient population 
in real-world clinical practice. Balugrastim has also been investigated in two phase 3 RCTs 
of patients with breast cancer and has an efficacy and safety profile comparable to that of 
pegfilgrastim. Again, further studies will determine whether this translates to other patient 
populations. Notably, the incidence of FN in the pegfilgrastim arms of the lipegfilgrastim 
and balugrastim studies (3% in cycle 1 for both studies [215,217]) was lower than in the 
registrational pegfilgrastim studies (9% and 7% in cycle 1 [224,225]), despite a similar 
study design and patient population. Maxy-G34 also appears to be non-inferior to 
pegfilgrastim; however, it was tested in only a very small number of patients (n = 35) [237]. 
BCD-017 and Ro 25-8315 did not appear to be as effective at reducing the incidence of 
FN as filgrastim [226,227].   
Because very few studies reported long-term outcomes of G-CSF use and two systematic 
reviews by Kuderer and Lyman et al. [263,264] looking at survival have previously been 
published, we did not include overall survival as an endpoint. In 2007, Kuderer et al. [263] 
published a systematic review of infection-related and early mortality during chemotherapy 
by type of G-CSF. They reported that there is insufficient data to draw conclusions. An 
updated analysis in 2013 by Lyman et al. [264] concluded that all-cause mortality is 
reduced in patients receiving chemotherapy with primary G-CSF support. However, Lyman 
et al. did not report results by type of G-CSF. We are still awaiting long-term survival data 
for the newer long-acting G-CSFs. Future research should examine in more detail the 
effects of long-acting G-CSFs on survival outcomes.  
As is true for all systematic reviews, the validity of our findings is limited by the quality of 
its underlying studies. Another limitation is that some studies did not report how many 
patients received primary prophylaxis versus secondary prophylaxis. This may have led to 
an underestimation of effectiveness. Furthermore, the studies were not all consistent in 
their definitions of FN and CIN and the number of chemotherapy cycles over which they 
reported data. Finally, combined measures of effect are missing in our analysis.  
It is clear that pegfilgrastim is widely used in clinical practice across a broad patient 
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population. Lipegfilgrastim and balugrastim were similar to pegfilgrastim in reducing the 
duration and incidence of CIN and FN in five studies. Furthermore, the safety profiles of 
the recently-developed long-acting G-CSFs were comparable to pegfilgrastim based on 
the phase 3 studies identified by this systematic review. These G-CSFs may prove to be 
valuable therapeutic options; however, there is a need for further studies in broader patient 
populations to confirm their effectiveness and safety in real-world clinical practice. New 
biosimilar G-CSFs and next-generation drugs targeting the G-CSF receptor are also in the 
early stages of development [212] and should be assessed against the current standard of 
care. 
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5 General discussion 
This work is based on four published studies based on observational data that addressed 
the epidemiology of CLL (4.1), the description of the epidemiology of neutropenia and 
febrile neutropenia including risk factors (4.2), the development and external validation of 
a risk prediction model for febrile neutropenia (4.3), and a systematic literature review on 
the efficacy of prophylactic measures for neutropenia (4.4).  
Our studies showed that primary care data from the UK CPRD seemed to be valid to 
determine the epidemiology of CLL, but unsuitable to evaluate the occurrence of 
neutropenia. In the hospital cohort of breast cancer patients, predictors of FN were blood 
parameters and genetic factors. The apparent predictive ability of the model was better 
than chance, but the model lacks external validation. In external validation of a risk 
prediction model in NHL patients, predictive performance of the model was only slightly 
lower than in the training dataset. Several options for preventing CIN or FN are available. 
If successful risk prediction models are developed, these may help to optimally target 
prophylaxis with G-CSFs to those patients at high risk of FN. Every study has its own 
discussion section reporting the limitations and strengths of the study designs and study 
findings.  
This general discussion puts the findings and contributions of the conducted studies in a 
broader context. It further reports the public health relevance and the implications of the 
studies taking into account other studies conducted in this field of research. 
Recommendations for ongoing and future studies are provided. Conclusions from the 
studies this work was based on are reported in a separate section following the general 
discussion section.   
5.1 Incidence of chronic lymphocytic leukaemia and neutropenia 
The majority of the population-based incidence rates of CLL reported in other studies are 
out of date. Several European studies were found that reported CLL incidence rates, but 
these incidence rates were calculated before the year 2010 [168,169]. Therefore, many 
studies addressing CLL-related topics repeatedly report CLL incidence rates of 3-
5/100’000 people or person-years. For some readers, this might suggest that CLL 
incidence rates did not change over the last 10 years. In contrast, a trend of increasing 
CLL incidence rates over the last 10 years was observed in the study conducted by the 
author. This observation is supported by a European study that also found an increase in 
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the incidences of leukaemias [57] and by reports from the UK [169].  
The analysis in the study conducted by the author covers the time period from 2000 to 
2012. Until 2008, the diagnosis of CLL relied on the National Cancer Institute Working 
Group criteria that have been introduced in 1996. New guidelines developed by the 
International Workshop on CLL (IWCLL) redefined CLL diagnosis criteria [265]. Molica et 
al. and Call et al. recently reported that using the new diagnosis guidelines, less early CLL 
cases were diagnosed [266,267]. Instead, patients that would have been diagnosed with 
early CLL according to the National Cancer Institute criteria were re-classified as 
monoclonal B-cell lymphocytosis, where patients can have a CLL phenotype, but no CLL 
symptoms such as lymphadenopathy or an enlarged spleen [268]. If the change in 
diagnosis criteria was not immediately implemented in clinical practice, but with a short 
delay, it could explain the temporary decrease in CLL incidence rates between the years 
2010 and 2011 observed in the UK CPRD. Because in the other years between 2000 and 
2012, an increase in CLL incidence rates was observed.  
Overall, the UK CPRD database was a valid approach to calculate CLL incidence rates for 
the UK. The International Lymphoma Epidemiology Consortium [269] aims to investigate 
the etiologies of NHL subtypes including CLL. Although the Consortium’s primary goal is 
to establish risk factors for the numerous subtypes of NHL, this could be an important future 
source to obtain nation-wide incidence rates of CLL. Published results by the Consortium 
include several European countries, but not Switzerland. In Switzerland, the cantonal 
cancer registry data are compiled by the Foundation National Institute for Cancer 
Epidemiology and Registration (nicer, http://www.nicer.org/de/). This cancer data are not 
publicly available. Nevertheless, summary statistics can be obtained from the nicer website 
and detailed information may be available upon request.  
As this is the first worldwide study assessing medical resource use in CLL patients, the 
study findings cannot be compared to other studies. During the time period from 2000 to 
2012, average medical resource utilisation per year in terms of number of recorded 
referrals and hospitalisations increased significantly. The observations were in line with 
key statistics of the UK National Health Service for the general population [175]. Possible 
reasons for the increase were explained in section 4.1 and included changes in the 
recording approach by GPs, changes in clinical practice patterns, the need for immediate 
treatment for some CLL patients. According to Molica et al. and Call et al., the change in 
diagnosis criteria led to a reduction in the time to first treatment of CLL patients [266,267]. 
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This may be an additional reason why the number of referrals and hospitalisations 
recorded in the UK CPRD increased that explains part of the increase. 
As mentioned in the study, the reported medical resource utilisation may only cover part of 
the total medical resource utilisation of CLL patients. CLL patients are often treated with 
chemotherapy, which is applied in secondary or tertiary care. CLL patients with 
chemotherapy-related complications such as infections or neutropenia are often 
hospitalised. This part of the medical resource utilisation may not be reflected in the primary 
care database. A recent study in elderly CLL patients of the USA using Medicare and a 
combination of linked databases showed that elderly patients often received chemotherapy 
with chlorambucil, rituximab, fludarabine or a combination of these chemotherapy drugs 
[270]. The study reported in this work also recorded prescriptions for CLL patients, but in 
comparison to the US study only few prescriptions for chemotherapy overall and no 
prescriptions for rituximab were recorded. Although the CPRD records referrals to 
specialists and hospitalisations, detailed information about these patient visits is missing. 
Linking the CPRD primary care database to other databases such as the hospital episode 
statistics may provide a more comprehensive overview on the medical resource utilisation 
of CLL patients. 
The author’s study (4.1) reported in this work is the most recent study that assessed 
population-based CLL incidence rates and to our knowledge, it is the first study assessing 
medical resource utilisation in CLL patients. Further studies assessing the trends in 
incidence rates of CLL should consider the change in diagnosis criteria of CLL when 
interpreting the study findings. Linkages to other than primary care databases may provide 
a better estimate of medical resource utilisation in CLL patients. 
5.2 Risk factors and risk prediction model of febrile neutropenia 
occurrence 
Several international guidelines base the initial assessment of the risk of CIN or FN on the 
applied chemotherapy regimen [98,141-143] conveying the impression that the applied 
chemotherapy regimen is a key predictor of CIN or FN occurrence. Based on that, the 
guidelines recommend the prophylaxis with G-CSFs if the risk of developing FN is more 
than 20%. The findings of the study conducted by Weycker et al. support the fact that the 
applied chemotherapy regimen determines a substantial part of the risk for FN occurrence 
[93]. They showed that prophylaxis with G-CSFs and/or antibiotics was mainly given to 
cancer patients receiving a chemotherapy regimen with a high or intermediate risk of 
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developing FN [93]. In these patients, G-CSF prophylaxis was given up to 75% of the 
patients, whereas in patients at low risk of FN G-CSF or antibiotic prophylaxis was given 
to about 20%. The guidelines recommend that patient risk factors are taken into account 
when the risk of developing FN with the planned chemotherapy regimen is intermediate 
(10-20%) [98,141]. 
To date, numerous studies reported risk factors of CIN and FN including patient-related, 
chemotherapy-related and tumour-related factors [104-109,111-120]. Blood count-related 
risk factors such as WBC, RBC, ANC or haemoglobin were the most commonly reported 
risk factors. A recent study by Lyman et al. summarised the available evidence on risk 
factors of FN and published a systematic literature review on risk factors for FN [110]. 
Some studies also reported protective factors [105,106,111,115]. Based on these studies, 
G-CSF prophylaxis and chemotherapy dose reductions or dose delays that occur before 
an FN event are effective in reducing the risk of FN. More recently, genetic factors were 
shown to be significant predictors of FN in various tumour types [121-126]. These risk 
factors have not yet been confirmed in multiple studies.  
Most of the reported studies above have in common that they focused on patient-related, 
chemotherapy-related and tumour-related factors or genetic factors. Those studies that 
included genetic factors only adjusted their estimate for certain patient-related and tumour-
related factors, but not for other risk factors that have been reported and published before 
[121-126]. One study this work is based on developed a risk prediction model for the 
occurrence of FN in breast cancer patients including patient-related, chemotherapy-
related, tumour-related characteristics and genetic factors. Not all of the previously 
published risk factors that were included in this study could be confirmed. Probably, some 
patient-related or tumour-related factors did not remain in the model, because the included 
genetic factors masked the effect of these risk factors. Another explanation could be that 
risk factors of FN that were reported in e.g. patients with haematological cancers or colon 
cancer patients do not apply to breast cancer patients and vice versa. This may challenge 
the development of one single risk prediction model that can be used for all types of 
cancers. Of the numerous genetic factors included as potential predictors of FN risk, two 
were identified that were associated with a very high risk of FN in a small subset of the 
study population. Before using these factors in decision-making on G-CSF prophylaxis in 
this subset of patients can be considered, the findings need to be confirmed by other 
studies. 
130 
 
 
 
Although several risk factors including genetic factors were combined in the study of this 
work, the predictive ability of the model was only acceptable and comparable to the 
predictive performance of former published studies not including genetic factors 
[105,106,113,127,130]. Possible reasons could be that some important previously reported 
risk factors or protective factors such as G-CSF prophylaxis and chemotherapy dose 
modifications could not be addressed in the model. All published models do not reliably 
identify patients that are likely to develop FN, but reliably identify patients that are unlikely 
to develop FN. Although it may be of benefit to know which patients probably do not need 
G-CSF prophylaxis, further refinement of these models to improve the PPV is necessary. 
Lyman et al. [110] published a comprehensive overview of risk factors for FN reported in 
the literature that could be helpful in designing future risk prediction models.   
A recently published risk prediction model by Pastor et al. used another approach to predict 
the occurrence of prolonged high grade neutropenia in cancer patients undergoing 
chemotherapy [271]. The authors developed a pharmacokinetic and pharmacodynamic 
model that described the neutrophil time course in cancer patients undergoing 
chemotherapy [272]. Based on this model, the authors derived decision rules for the 
prophylactic application of G-CSFs [271]. The model only included ANC measures at 
different time points of the chemotherapy cycle as a predictor of FN risk. Predictive 
performance of the model was good with a resulting area under the ROC curve of 0.875. 
Because blood count data are routinely measured in cancer patients undergoing 
chemotherapy, this model approach could complement other model development 
approaches. The combination of ANC counts at different time points and patient-related, 
chemotherapy-related, tumour-related and genetic factors may improve the predictive 
performance of the risk prediction model in external validation to an extent such that the 
model can be useful in clinical practice.   
The risk prediction models of neutropenia presented in this work need further refinement 
to improve the predictive ability of the models. Based on the results of the above presented 
models, the impact of genetic factors that are associated with multidrug resistance or 
metabolism of chemotherapy drugs on the occurrence of CIN or FN in cancer patients 
should be further evaluated. Another approach to refine neutropenia risk prediction models 
is to determine the impact of frailty including comorbidity on the occurrence of neutropenia.  
Another important step towards the development of an international applicable neutropenia 
risk prediction model would be the combination of available datasets in cancer patients 
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looking at neutropenia occurrence. If the collected data would be comparable and could 
be combined to a single, comprehensive dataset, it might further improve the predictive 
ability of risk prediction models in neutropenia. The resulting risk prediction model should 
be externally validated in an independent dataset. Optimally, by performing a prospective 
study that applies the resulting risk scores to patients undergoing chemotherapy to help 
identify patients at low or high risk of neutropenia.  
5.3 External validation of a risk prediction model of febrile neutropenia 
occurrence 
Internal validity of a risk prediction model can be determined quite easily using the same 
population as the model was developed in. Several techniques are available such as split-
sample validation, cross-validation and bootstrapping that help to determine if the model 
does what it was intended to do. But internal validation does not provide evidence about 
the generalisability of the model of interest. External validity is a measure of how the model 
works in an independent population or other settings.  
External validations of risk prediction models in general are rare [201]. Jenkins et al. 
performed a partial validation of their original model [104] using an independent dataset 
[108]. The original predictive model was developed in breast cancer patients and included 
the ANC and the absolute lymphocyte count. In addition, the Jenkins’ model [104] was 
externally validated by other researchers. Chen et al. tested the Jenkins’ model in breast 
cancer patients without pre-specifying successful validation criteria [135]. They concluded 
that the Jenkins’ model did not accurately identify patients at high risk of FN and that the 
model should be expanded by including the absolute monocyte count [135].  
Predictive ability in the external validation of the model of FN occurrence in NHL patients 
undergoing chemotherapy was lower than the pre-defined successful validation criteria. 
Therefore, the model was judged inappropriate to be used in clinical practice. Other studies 
also observed a slight decrease in model performance in internal validation 
[105,106,113,127,130] and therefore, it was not surprising that we observed a decrease in 
external validation. Possible reasons could be the differences in the variable definitions or 
the difference in population size of the two data sources. Although the two databases were 
quite comparable, some variables available in the training dataset were not available in the 
validation dataset and vice versa. In addition, the smaller study was used for the model 
development and the bigger study for the model validation. On the one hand, it would 
speak in favour of the validity of the developed model if it could successfully predict FN 
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occurrence in the bigger population. On the other hand, the model performance in external 
validation could have been better with the model being developed in the bigger population. 
Nevertheless, probably neither of the models would have been applicable for clinical use.  
Several risk prediction models for CIN and FN based on risk factors have been developed. 
Up to now, no model is validated and clinically used. The observed differences in model 
performance under different conditions, especially the decrease in model performance 
using an independent dataset, confirm the importance of external validation before risk 
models are put to clinical use [134]. If the prediction and external validation is successful, 
further steps about the implementation of the risk score in clinical practice should be 
initiated.  
As mentioned above, validated risk models would only be of clinical use if they supported 
physicians’ treatment decisions [207]. Ideally, the results of a prediction model should be 
transferred to a simplified risk score. The resulting risk score should be as straightforward 
as possible to be easily implemented into clinical practice. Clinicians are probably not 
willing to apply the risk score in their daily practice if it takes too much time to evaluate the 
individual risk for FN of a patient based on the risk score. Therefore, it is of utmost 
importance that clinicians are involved early in the development of a potential risk score. 
The results should be disseminated in collaboration with clinicians. Other researchers and 
public health systems should get access to the risk prediction score to increase awareness 
of the potential use of the score and to improve it on an ongoing basis. 
Furthermore, it is also important to highlight that the aim of risk prediction models is not to 
replace the decision-making process of clinicians. When assessing the risk of CIN or FN 
in a cancer patient undergoing chemotherapy, the experience of a clinician adds 
substantial information to the assessment of patient-related and chemotherapy-related 
factors. Instead, a risk score should be a reliable support for the clinician to make the 
decision about the administration of supportive measures or not. 
5.4 Systematic literature review of granulocyte colony-stimulating factors 
Previously published systematic reviews and meta-analyses on the efficacy of G-CSFs 
only included randomised controlled trials (RCTs) and concluded that G-CSFs are effective 
and safe for the prophylaxis of FN [261,262]. Recently, a narrative review of G-CSFs as 
prophylaxis of FN was published [273]. All systematic reviews showed consistent results 
regarding the efficacy of G-CSFs as prophylaxis against neutropenia. However, efficacy 
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results very often do not tell us if G-CSFs have the same effect under real-life conditions. 
There is growing evidence in the literature that efficacy does not directly translate into 
effectiveness because issues of generalisability and external validity are seldom 
considered [274,275]. 
Compared to these systematic reviews, the review included in this work also considered 
clinical trials and observational studies and still came up to the same conclusions. A 
disadvantage of this approach is that the risk of bias in clinical trials and observational 
studies is higher than the risk of bias in RCTs. In RCTs, patients are randomly assigned to 
an intervention or a comparator, whereas allocation does not have to be at random in 
clinical trials or is not at random in observational studies. This may introduce bias and 
confounding. Therefore, the findings from observational studies should be carefully 
interpreted. On the other hand, results from observational studies are more generalisable. 
In RCTs, G-CSFs are used in an ideal setting according to guidelines or a pre-defined 
protocol. Observational studies more appropriately reflect the use of G-CSF in clinical 
practice. 
In clinical practice, there is a wide variability in the use of G-CSFs [276,277]. Many patients 
receive GCSFs not according to guideline recommendations. Sometimes GCSFs are not 
administered although recommended by guidelines and vice versa [278]. A literature 
review showed that the administration of prophylactic daily G-CSFs such as filgrastim not 
according to guideline recommendations led to compromised patient outcomes due to CIN 
or FN [273]. In cases where prophylactic G-CSF has not been assigned and cancer 
patients develop FN, it has been shown that appropriate FN management plays an 
important role to avoid further complications. The study by Meisenberg et al. showed that 
concordance with guidelines, staff and patient education, and implementation of 
standardised treatment pathways for FN improve FN management [279].  
There are other supportive options available to prevent the occurrence of CIN, FN or 
related complications in cancer patients. Antimicrobial prophylaxis has been 
recommended by the American Society of Clinical Oncology if patients are at risk of 
prolonged neutropenia or other neutropenia-related complications and infections that 
increase the risk of mortality [144]. Studies showed that antimicrobials are effective in 
treating FN [280,281] and time to antibiotic administration may influence mortality [282]. 
Correct antibiotic or antifungal administration can be essential when treating neutropenia-
related infections [100,282]. The issue with antibiotic prophylaxis is the potential of 
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antibiotic resistance, which does not apply to G-CSFs. One downside of G-CSFs is that 
they are costly [283]. But if risk prediction models can be successfully validated and support 
clinical decision-making, they may improve the cost-effective use of G-CSFs. 
Overall, G-CSFs substantially impacted on the prophylaxis and treatment of neutropenia. 
Although available G-CSFs such as filgrastim and pegfilgrastim have been successful and 
are commonly used, numerous new biosimilar G-CSFs are in development. Companies 
are also interested in developing other G-CSF agonists that activate the G-CSF receptor 
in a different way which could lead to an additive effect or increased efficacy of G-CSFs 
[212].  
Even with the development of new-acting G-CSFs, it might be challenging to outreach the 
already achieved efficacy of G-CSFs [212]. In this case, harmonisation of guidelines and 
clear recommendations for the use of G-CSFs in clinical practice are another important 
step to translate efficacy of RCTs into clinical practice and increase the effectiveness of G-
CSFs [212]. 
5.5 Implications 
In research in general, the availability of data and access to appropriate data sources is 
essential. Often, epidemiological studies are conducted using sub-samples of the 
populations of interest, e.g. patients visiting a specific health care provider or patients being 
enrolled in a specific study. These population sub-samples may not be representative of 
the entire population of interest and may lead to biased estimates. More reliable data 
sources for the assessment of incidence or prevalence rates of certain diseases could be 
nationwide primary care databases such as the CPRD in the UK or nationwide disease 
registries such as cancer registries in e.g. the Netherlands, Switzerland or USA. Depending 
on the type of disease, primary care databases or disease registries are more appropriate. 
For example, chronic diseases such as diabetes are monitored by primary care physicians 
and can be captured in primary care databases. For diseases where referrals to specialists 
or hospitals are often such as cancer, disease registries may provide a more 
comprehensive picture of the disease. 
Risk prediction models or risk scores are developed to help to identify patients at high risk 
of a certain event or outcome. In regard to the successful development of these tools and 
the application in clinical practice, external validation is necessary. As it is difficult to get 
access to independent datasets, research policies should be in place that support data 
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sharing among researchers. Ideally, financed research programs should be available that 
allow the systematic validation of promising risk prediction models and risk scores in 
independent datasets. In order to facilitate collaboration among researchers, these 
research programs should be initiated by the government and gradually be handed over to 
research councils that guide and monitor the systematic validation in independent 
datasets. 
To achieve an evidence-based and efficient management of patients, research results 
regarding risk prediction models and risk scores should be disseminated and available to 
the public. If a successful risk score has been developed and validated, recommendations 
or guidelines for patient management set up by the government in collaboration with 
researchers and clinicians may anticipate implementation in clinical practice. Further, 
standardisation of patient management approaches may improve patient outcomes.   
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6 Conclusions 
Our studies showed that primary care databases can be used to calculate incidences of 
cancer and obtain medical resource utilisation of cancer patients in primary care. In only 
few cases, the database recorded information on the type of chemotherapy, on 
neutropenia occurrence, and on the use of G-CSFs. Linkage to databases from secondary 
and tertiary care settings would be necessary to obtain details about chemotherapy and 
derive the incidence of neutropenia in cancer patients.  
Neutropenia in cancer patients undergoing chemotherapy is a relevant clinical issue. 
Depending on the chemotherapy regimen applied and the presence of other potential risk 
factors of neutropenia, the risk of CIN and FN varies. Evaluating the impact of genetic 
factors on neutropenia occurrence in cancer patients is a younger field of interest. 
Therefore, further studies including genetic factors are necessary.  
Adding genetic factors did not much improve the predictive performance of the neutropenia 
risk prediction model presented in this work. The limited predictive ability of the model in 
the training dataset showed that further evaluation of risk factors is necessary. Because 
predictive performance of another model was lower in external validation, careful clinical 
decision making until validated models are available with adequate predictive ability is of 
utmost importance. There is a clear need for further studies and continuing validation of 
proposed risk predictors and tools. 
Validated prediction models with adequate predictive ability may help to optimally target 
prophylaxis with G-CSFs to those patients at high risk of CIN or FN. Several daily and long-
acting G-CSFs such as filgrastim, lenograstim, pegfilgrastim, balugrastim and 
lipegfilgrastim are available that reduce the incidence of CIN, FN and related 
hospitalisations or antibiotic use. The development of new valuable supportive options is 
ongoing. In times of increasing health care costs and scarce resources, the cost-effective 
use of supportive measures may become necessary. 
Availability of and access to appropriate data sources are necessary to develop and 
validate risk prediction models to target G-CSF prophylaxis to patients at high risk of FN 
as has been shown by the studies this work is based on. These studies further contribute 
to the development of an evidence-based, efficient and cost-efficient approach to prevent 
neutropenia in cancer patients.
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8 Appendix 
8.1 Supplementary material for 4.4 
Table 8.1-1: Detailed search strategy 
 Searches EMBASE Hits 
#1 exp recombinant granulocyte colony stimulating factor/ or filgrastim.mp. 12170  
#2 pegylat*.mp. 12216  
#3 1 and 2 392  
#4 ($pegfilgrastim or SD01 or neulasta or neulastim or imupeg).mp. 1150  
#5 (PEG-rmetHuG-CSF or polyethylene glycol-conjugated filgrastim).mp. 2  
#6 
(balugrastim or CG-10639 or lipegfilgrastim or XM-22 or glycopegylated C-
CSF).mp. 
5  
#7 
(lonquex or neugranin or albugranin or SPI-2012 or LAPS-GCSF or 
HM10460A).mp. 
6  
#8 (Extimia or BCD-017).mp. 0  
#9 3 or 4 or 5 or 6 or 7 or 8 1381  
#10 exp cancer chemotherapy/ or exp chemotherapy/ or chemotherapy.mp. 491608  
#11 cancer.mp. or exp neoplasm/ 3447398  
#12 (tumor or tumour).mp. 1939478  
#13 10 or 11 or 12 3783824  
#14 
exp neutropenia/ or neutropenia.mp. or exp febrile neutropenia/ or exp severe 
congenital neutropenia/ 
73934  
#15 9 and 13 and 14 734  
#16 limit 15 to (human and English language) 578  
 Search Cochrane Library Hits 
#1 MeSH descriptor: [Granulocyte Colony-Stimulating Factor] explode all trees 1018 
#2 *filgrastim  653 
#3 pegylat*  959 
#4 (#1 or #2) and #3  34 
#5 $pegfilgrastim or SD01 or neulasta or neulastim or imupeg  136 
#6 PEG-rmetHuG-CSF or polyethylene glycol-conjugated filgrastim  1 
#7 balugrastim or CG-10639 or lipegfilgrastim or XM-22 or glycopegylated C-CSF  144 
#8 lonquex or neugranin or albugranin or SPI-2012 or LAPS-GCSF or HM10460A  0 
#9 Extimia or BCD-017  0 
#10 #4 or #5 or #6 or #7 or #8 or #9  302 
#11 chemotherapy  31372 
#12 MeSH descriptor: [Neoplasms] explode all trees 44664 
#13 cancer or oncology  73625 
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#14 MeSH descriptor: [Neutropenia] explode all trees  
#15 tumor or tumour 20482 
#16 #11 or #12 or #13 or #14 or #15  91759 
#17 MeSH descriptor: [Neutropenia] explode all trees 1346 
#18 neutropenia  3855 
#19 #17 or #18  3855 
#20 #10 and #16 and #19  82 
 Searches MEDLINE & MEDLINE InProcess Hits 
#1 exp Granulocyte Colony-Stimulating Factor/ 28724  
#2 $filgrastim.mp. 3198  
#3 pegylat*.mp. 12216  
#4 (1 or 2) and 3 442  
#5 ($pegfilgrastim or SD01 or neulasta or neulastim or imupeg).mp. 1150  
#6 (PEG-rmetHuG-CSF or polyethylene glycol-conjugated filgrastim).mp. 2  
#7 
(balugrastim or CG-10639 or lipegfilgrastim or XM-22 or glycopegylated C-
CSF).mp. 
5  
#8 (lonquex or neugranin or albugranin or SPI-2012 or LAPS-GCSF or HM10460A).mp. 6  
#9 (Extimia or BCD-017).mp. 0  
#10 5 or 6 or 7 or 8 or 9 1159  
#11 chemotherapy.mp. 459728  
#12 cancer.mp. or exp Neoplasms/ 3447398  
#13 oncology.mp. or exp Medical Oncology/ 143668  
#14 (tumor or tumour).mp. 1939478  
#15 11 or 12 or 13 or 14 3795647  
#16 neutropenia.mp. or exp Neutropenia/ 73934  
#17 10 and 15 and 16 675  
#18 limit 17 to (human and english language) 532  
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Table 8.1-2: Definitions of outcome measures 
Outcome Definition Used by 
Febrile 
neutropenia 
- oral temperature ≥ 38°C and ANC <0.5x109/L 
- oral temperature ≥ 38°C for more than 1h and ANC 
<0.5x109/L 
- oral temperature ≥ 38.2°C and ANC <0.5x109/L 
- oral temperature ≥ 38.3°C and ANC <0.5x109/L 
- oral temperature ≥ 38.5°C and ANC <0.5x109/L 
- oral temperature ≥ 38°C and ANC <1.0x109/L 
- oral temperature ≥ 38.2°C and ANC <1.0x109/L 
- oral temperature ≥ 38.3°C and ANC <1.0x109/L 
- oral temperature > 38.5°C and ANC <1.0x109/L 
[208,209,221,227] 
[147,230,231,246,249] 
 
[220,235,250,253,261] 
[147,210,246,249] 
[227,230,236] 
[209,215,264] 
[229,253] 
[246] 
[264] 
Neutropenia - Grade 3/4 or severe: ANC <1.0x109/L 
- Grade 4 or severe: ANC <0.5x109/L 
[143,208,209,227,229,246,253,254] 
[143,209,220,235,246,253,262] 
Hospitalisation - due to infection ICD-9-CM 001.x-139.x 
- due to febrile neutropenia ICD-9-CM 288.0 and ICD-9-
CM 780.6 
- neutropenia ICD-9-CM 288.0 or fever ICD-9-CM 780.6 
[228] 
[228] 
 
[231,247] 
Chemotherapy 
dose delivery 
- dose reductions (≥15% of standard doses) 
- (1-dose received/dose planned)% 
- dose reduction (<80% of chemotherapy dose in cycle 1) 
- dose delays (≥7 days) 
- dose delays (>3 days) 
- full dose on schedule (≤15% dose reduction and ≤3 days 
dose delay) 
- planned dose on time (≥80% of planned dose and ≤3 
days dose delay) 
[106,208,210,250] 
[249] 
[209] 
 
[209,250] 
[106,208,210,249] 
[254] 
 
[261] 
Adverse 
events 
CTCAE v.3.0 
CTCAE V.4 
WHO toxicity criteria 
[143,234,242,251] 
[250] 
[261] 
ANC, absolute neutrophil count; CTCAE, Common Terminology Criteria for Adverse Events; ICD, International 
Classification of Diseases, Ninth Revision, Clinical Modification; WHO, World health organization 
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